DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         1 
 Abbreviated Title: Study on the safety and immunogenicity of 
Boostrix vaccine in pregnant Malian women and their infants  
A Phase II Double- blind Trial to Evaluate the Safety, 
Immunogenicity and Effect on Infant Immune Responses of a Single 
Dose of Tdap in Pregnant Women in Mali  
DMID Protocol Number:  16-0024 
DMID Funding Mechanism: Vaccine and Treatment Evaluation Units  
Pharm aceutical Support Provided by: [CONTACT_452366]: Division of Microbiology and Infectious Diseases, National Institute of 
Allergy and Infectious Diseases, National Institutes of Health 
Lead Principal Investigator:  [INVESTIGATOR_452331] M. Neuzil, MD, MPH; University of Maryland 
School of Medicine, Center for Vaccine Development  
Contract PI/Co -investigator:   Karen L. Kotloff, MD; University of Maryland School of 
Medicine, Center for Vaccine Development  
Site PIs  : Milagritos Tapia, MD U niversity of Maryland School of Medicine, Center for 
Vaccine Development  
Samba O. Sow MD., MSc., Centre pour le Développement des Vaccins – Mali, Bamako, 
Mali  
Site Investigators: Fadima Cheick Haidara MD., Fatoumata Diallo MD., Moussa Doumbia 
MD., Flanon  Coulibaly MD., Djeneba Traoré MD., Ibrahima Téguété MD., Awa Traoré 
PharmD. , Mamoudou Kodio PharmD., Uma Onwuchekwa,  Centre pour le Développement 
des Vaccins – Mali, Bamako, Mali 
DMID Clinical Project Manager: Wendy Buchanan, BSN, MS  
DMID Scientific Lead:  Kristina T. Lu, PhD 
DMID Medical Officer:  Francisco Jose Leyva, MD, PhD, ScM 
DMID Medical Monitor:  Mohamed M. Elsafy, MD 
Draft or Version Number: 3.0 
24 July 2019  
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         2 
 STATEMENT OF COMPLIA NCE 
This trial will be carried out in accordance with Good Clinical Practice (GCP) as required by [CONTACT_14504]: 
• [LOCATION_002] Code of Federal Regulations (CFR) 45 CFR Part 46: Protection of 
Human Subjects 
• Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50 (Protection of Human Subjects), 21 CFR P art 54 (Financial Disclosure by [CONTACT_1615]), 21 CFR Part 56 (Institutional Review Boards), 21 CFR Part 11, and 21 CFR Part 312 (Investigational New Drug Application), 21 CFR 812 (Investigational Device Exemptions)  
• International Conference on Ha rmonisation: Good Clinical Practice (ICH E6); 62 
Federal Register [ZIP_CODE] (1997); and future revisions 
• Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research  
• National Institutes of Health (NIH) Office of Extramural Research  (OER) , Research 
Involving Human Subjects, as applicable 
• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award, as applicable  
• Applicable Federal, State, and Local Regulations and Guidance 
Compliance with these standards provides public assurance that the rights, safety, and well- being 
of trial subject s are protected, consistent with the principles that have their origin in the 
Declaration of Helsinki.  
All key personnel (all individuals responsible for the design and conduct of this trial) have 
completed Human Subjects Protections Training. 
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         3 
 SIGNATURE [CONTACT_452463] t hat this trial will be conducted according 
to all stipulations of the protocol, including all statements regarding confidentiality, and 
according to local legal and regulatory requirements and applicable US federal regulations and 
ICH E6 Good Clinical Prac tice (GCP) guidelines.  
I agree to conduct the study in compliance with GCP and applicable regulatory requirements. 
I agree to conduct the study in accordance with the current protocol and will not make changes to 
the protocol without obtaining the sponsor’s approval and Institutional Review Board  
(IRB)/Institutional Ethics Committee (IEC) approval, except when necessar y to protect the 
safety, rights, or welfare of subjects.  
 
Lead Principal Investigator (CVD Baltimore):  
Signed:  
 Date:   
 Name  
[CONTACT_452464] (CVD Mali):  
Signed:  
 Date:   
 Name  
[CONTACT_422774] 16- [ADDRESS_576695] Replacement  ..................................................................................................49  
5.3.6.  Termination of Study ..................................................................................................49  
6. STUDY INTERVENTION/I NVESTIGATIONAL PRODUCT  ...............................[ADDRESS_576696] Storage and Stability .....................................................................................52  
6.2. Dosage, Preparation and Administration of Study 
Intervention/Investigational Product ..........................................................................52  
6.2.1.  BOOSTRIX  ................................................................................................................53  
6.2.2.  Td Control Vaccine .....................................................................................................53  
6.2.3.  Administration  ............................................................................................................54  
6.3. Modification of Study Intervention/Investigational Product for a Subject ................54  
6.4. Accountability Procedures for the Study Intervention/Investigational Product(s) ....................................................................................................................[ADDRESS_576697] Compliance with Study Intervention/Investigational Product/Investigational Device  ...................................................................................55
 
6.6. Concomitant Medications/Treatments  ........................................................................55  
7. STUDY SCHEDULE  .................................................................................................56  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         6 
 7.1. Recruitment  .................................................................................................................56  
7.2. Screening  ....................................................................................................................56  
7.3. Enrollment/Baseline  ...................................................................................................57  
7.4. Follow-up ....................................................................................................................58  
7.4.1.  Clinic or Home Visits  .................................................................................................59  
[IP_ADDRESS].  Post Study Vaccination Follow-up Visit, Day 4 (±1 d): Home Visit, Pregnant 
Women (Visit 02 or V02) ...........................................................................................59  
[IP_ADDRESS].  Post Study Vaccination Follow-up Visit, Day 8 (+3 d): Home Visit, Pregnant Women (Visit 03 or V03) ...........................................................................................59
 
7.4.2.  Clinic Visits  ................................................................................................................60  
[IP_ADDRESS].  Immunology and Safety Follow-up Visit, [ADDRESS_576698] Study Vaccination Visit, Day 31 (±4 d): Clinic Visit, Pregnant Women (Visit 04 or V04) .....................60
 
[IP_ADDRESS].  Subsequent Follow- up Visits  ......................................................................................60  
[IP_ADDRESS].1.  Labor and Delivery Visit, Birth (+3 d): Clinic Visit, Pregnant Women and Infants (Visit 05 or V05) .............................................................................................60
 
[IP_ADDRESS].2.  6 Weeks Postpartum Safety Follow-up Visit, Birth + Day 42 (±5 d): Clinic Visit, Postpartum Women and Infants (Visit 06 or V06) ...........................................62
 
[IP_ADDRESS].3.  10 or 18 Weeks Postpartum Safety Follow-up Visit, Birth + Day 70 (±5 d) or Birth + Day 130 (±5 d): Clinic Visit, Postpartum Women and Infants (Visit 07 or V07) ...................................................................................................................62
 
7.5. Final Study Visit  .........................................................................................................63  
7.6. Early Termination Visit (if needed)  ............................................................................63  
7.7. Unscheduled Visit (if needed) ....................................................................................64  
8. STUDY PROCEDURES/EVALUATIONS  ...............................................................66  
8.1. Clinical Evaluations  ....................................................................................................66  
8.2. Laboratory Evaluations ...............................................................................................67  
8.2.1.  Clinical Laboratory Evaluations .................................................................................67  
8.2.2.  Special Assays or Procedures  .....................................................................................68  
8.2.3.  Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007] .........................................................70  
[IP_ADDRESS].  Instructions for Specimen Preparation, Handling, and Storage ..................................70  
[IP_ADDRESS].  Specimen Shipment ....................................................................................................70  
9. ASSESSMENT OF SAFETY  .....................................................................................71  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         7 
 9.1. Specification of Safety Parameters  .............................................................................71  
9.2. Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  ...................................................................................................................72  
9.2.1.  Adverse Events  ...........................................................................................................72  
9.2.2.  Reactogenicity (for Vaccine Studies and Some Therapeu tic Trials)  ..........................[ADDRESS_576699] Values or Abnormal Clinical Findings  ...................................................................................83
 
9.3. Reporting Procedures ..................................................................................................83  
9.3.1.  Serious Adverse Events ..............................................................................................84  
9.3.2.  Regulatory Reporting for Studies Conducted Under DMID- Sponsored IND  ............84  
9.4. Type and Duration of Follow-up of Subjects after Adverse Events ...........................85  
9.5. Halting Rules  ..............................................................................................................85  
9.6. Safety Oversight (ISM plus SMC or DSMB) .............................................................86  
9.6.1.  Independent Safety Monitor (ISM) ............................................................................[ADDRESS_576700] (DSMB) ..............................................................87  
10. CLINICAL MONITORING .......................................................................................89  
10.1.  Site Monitoring Plan  ...................................................................................................89  
11. STATISTICAL CONSIDERATIONS  .......................................................................90  
11.1.  Study Hypotheses  .......................................................................................................90  
11.2.  Sample Size Considerations .......................................................................................90  
11.2.1.  Study Design  ...............................................................................................................90  
11.2.2.  Study Population .........................................................................................................90  
11.2.3.  Sample Size  ................................................................................................................91  
11.3.  Planned Interim Analyses  ...........................................................................................93  
11.3.1.  Interim Safety Review  ................................................................................................93  
11.3.2.  Interim Immunogenicity or Efficacy Review  .............................................................93  
11.4.  Final Analysis Plan  .....................................................................................................94  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         8 
 11.4.1.  Analysis Populations ..................................................................................................94  
11.4.2.  Safety Data  ..................................................................................................................95  
11.4.3.  Immunogenicity Data (ELISA)  ..................................................................................95  
11.4.4.  Missing Values and Outliers  .......................................................................................96  
12. SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  ...............................................................................................97  
13. QUALITY CONTROL AND QUALITY ASSURANCE  .........................................98  
14. ETHICS/PROTECTION OF  HUMAN SUBJECTS  ..................................................[ADDRESS_576701]  .........................................................................................99  
14.3.  Informed Consent Process ..........................................................................................99  
14.3.1.  Informed Consent/Assent Process (in Case of a Minor) ..........................................101  
14.4.  Exclusion of Women, Minorities, and Children (Special Populations) ....................[ADDRESS_576702] KEEPI[INVESTIGATOR_1645]  ....................................................105  
15.1.  Data Management Responsibilities  ..........................................................................105  
15.2.  Data Capture Methods  ..............................................................................................105  
15.3.  Types of Data  ............................................................................................................105  
15.4.  Timing/Reports  .........................................................................................................[ADDRESS_576703] OF TABLES  
Table 1: Treatment Arms and Study Vaccine to be Administered  ................................................22  
Table 2: Specimen Volumes (mL) for Pregnant Women and Infants ...........................................69  
Table 3: Local (Injection Site) Reactogenicity Grading  ................................................................74  
Table 4: Local (Injection Site) Reactogenicity Measurements  ......................................................75  
Table 5: Subjective Systemic Reactogenicity Grad ing ..................................................................76  
Table 6: Quantitative Systemic Reactogenicity Grading  ...............................................................77  
Table 7: Pulse and Blood Pressure Severity Grading ....................................................................77  
Table 8: Maternal and Infant Adverse Events  ...............................................................................78  
Table 9: Power (%) to Detect Safety Events  .................................................................................91  
Table 10: Precision for Estimating GMC of ELISA Antibody Response .....................................92  
Table 11: Minimum Detectable Difference in Infant PT Antibody GMC at Birth 
Comparing Infants Born to Mothers Vaccinated with BOOSTRIX versus Td ..........[ADDRESS_576704] OF FIGURES  
Figure 1: Schematic of Study Design  ............................................................................................[ADDRESS_576705] OF ABBREVIATION S 
ACIP  Advisory Committee on Immunization Practices, CDC  
ACOG  American College of Obstetrics and Gynecology  
AE Adverse Event/Adverse Experience  
AGA  Appropriate for Gestational Age  
ASQ -3 Ages and Stages Questionnaire -3 
BMI  Body Mass Index  
BP Blood Pressure  
bpm Beats per Minute  
CDC  Centers for Disease Control and Prevention  
CFR  Code of Federal Regulations  
CI Confidence Interval  
cm Centimeter  
CMS  Clinical Materials Services  
CNAM  Centre Nationale à la lutte contre la Maladie  
CRM 197 a form of diphtheria toxoid  
CROMS  Clinical Research Operations and Management Support  
CSR  Clinical Study Report  
CVD  Center for Vaccine Development  
CVD -Mali  Center for Vaccine Development - Mali  
°C Degrees Celsius  
°F Degrees Fahrenheit  
D Day(s)  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases  
DSMB  Data and Safety Monitoring Board  
DTwP  Diptheria, Tetanus, and whole -cell Pertussis Vaccine  
eClinicalSM Electronic Data Capture System  
eCRF  electronic Case Report Form  
e.g. for example  
EGA  Estimated Gestational Age  
ELISA  Enzyme -Linked Immunosorbent Assay  
EPI [INVESTIGATOR_452332] 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         12 
 FHA  Filamentous Hemagglutinin  
FIM 2  Fimbriae 2  
FIM 3  Fimbriae 3  
FW Field Worker  
FWA  Federalwide Assurance  
g/dL  Grams per Deciliter  
GA Gestational Age  
GBS  Guillain -Barré Syndrome  
GCP  Good Clinical Practices  
gDM  Gestational Diabetes Mellitus  
GMC  Geometric Mean Concentration  
GMR  Geometric Mean Ratio  
GMT  Geometric Mean Titer  
[COMPANY_004]  GlaxoSmithKline Biologicals  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
IATA  International Air Transport Association  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device  Exemption  
i.e. that is  
IEC Independent or Institutional Ethics Committee  
IFN Interferon  
IgA Immunoglobulin A  
IL Interleukin  
IM Intramuscular  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
ITT Intent -to-Treat  
LGA  Large for Gestational Age  
LMP  Last Menstrual Period  
MAPT  Multicenter Acellular Pertussis Trial  
mcg or µg  Microgram (s) 
MD Doctor of Medicine  
MedDRA Medical Dictionary for Regulatory Activities  
mg Milligram (s) 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         13 
 mg/dL  Milligram(s) per Deciliter  
mL Milliliter(s)  
mm Millimeter(s)  
mm Hg  Millimeters of Mercury  
MOP  Manual of Procedures  
MPH  Master of Public Health  
MS or MSc  Master of Science  
MSD  Meso Scale Diagnostic  
N Number of Subjects  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
OER  Office of Extramural Research (NIH)  
OHRP  Office for Human Research Protections  
PBMC  Peripheral Blood Mononuclear Cells  
PERCH  Pneumonia Etiology Research for Child Health  
PHI Personal/Protected Health Information  
PI [INVESTIGATOR_452333](D)  Rhesus Antigen D (a red blood cell surface protein)  
SAE  Serious Adverse Event/Serious Adverse Experience  
SBA  Serum Bactericidal Antibody  
SGA  Small for Gestational Age  
SOC  System Organ Class  
SOP Standard Operating Procedure  
Td Tetanus Diphtheria Toxoid  
Tdap  Tetanus Diphtheria Acellular Pertussis Vaccine  
Th T Helper Cell  
TNF  Tumor Necrosis Factor  
TT Tetanus Toxoid  
[LOCATION_006] [LOCATION_008]  
US [LOCATION_002]  
USP [LOCATION_002] Pharmacopeial Convention  
V Visit  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         14 
 VAERS  Vaccine Adverse Event Reporting System  
vs.  Versus  
VTEU  Vaccine and Treatment Evaluation Unit  
VVM  Vaccine Vial Monitor  
WBC  White Blood Cells  
WFI Water for Injection  
WHO  World Health Organization  
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         15 
 PROTOCOL SUMMARY  
Title:  A Phase II Double -Blind Trial to Evaluate the Safety, 
Immunogenicity, and Effect on Infant Immune Responses of a 
Single Dose of Tdap in Pregnant Women in Mali  
Phase:  2 
Population:  200 healthy pregnant women, ages 18 through 39 years, 
inclusive, who meet all eligibility criteria, and their infants  
Number of Sites:  
  Study Site:  At least one Vaccine and Treatment Evaluation Unit (VTEU) -
subcontracted site  Referral Health Center of Commune I (CSREF I) of the district 
of Bamako, Mali 
 
Study Duration:  21 months: Approximately [ADDRESS_576706] s, and 13 months (3-7 months while 
pregnant and 6 months postpartum) from last subject  vaccinated 
until she and her infant complete follow -up 
Subject Participation Duratio n: Pregnant subjects: Approximately 10-13 months; infants: 
approximately 6 months  
Description of Agent or 
Intervention:  Test agent: A single dose of Tetanus, diphtheria, acellular pertussis ( Tdap ) (BOOSTRIX) manufactured by 
[CONTACT_145600] ( [COMPANY_004]) and administered 
intramuscularly at a volume of 0.5 milliliter (mL) or Control agent: a single dose of Tetanus diphtheria toxoid ( Td) 
intramuscularly at a volume of 0.5 mL.  
Objectives : 
 Primary:  
Safety and Tolerability : 
• To assess the safety and tolerability of a single 0.5 mL 
intramuscular injection of BOOSTRIX in pregnant women. 
• To assess the safety of a single maternal BOOSTRIX 
vaccination on the fetus and infant.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         16 
 Immunogenicity:  
• To assess the level of PT antibody at birth among infants 
whose mothers received a single dose of BOOSTRIX or Td while pregnant. 
 Secondary:  
Immunogenicity : 
• To assess the antibody response to BOOSTRIX vaccine 
antigens in pregnant women one month after receipt of 
BOOSTRIX, at the time of delivery, and at 6 months 
after delivery.  
• To compare the antibody levels of BOOSTRIX vaccine antigens at birth (cord blood) and 6 weeks of age (before receiving any infant doses of  Diphtheria, Tetanus, and 
whole- cell Pertussis  (DTwP )) in infants whose mothers 
received BOOSTRIX or Td during pregnancy.  
• To assess placental antibody transfer by [CONTACT_452367] -specific 
antibody responses at delivery. 
• To assess interference with infant antibody responses to DTwP either prior to the second dose of the prima ry 
DTwP series, at approximately 10 weeks of age (in ½ of 
subject s), or approximately one month after the third 
dose of the primary DTwP series, at approximately 18 weeks of age (in ½ of subject s), and at 6 months of age 
(all subject s). 
 Exploratory: 
Immunogenicity : 
• To assess the effects of maternal age, parity, gestational 
age (GA) at which the vaccine is given, GA at delivery, 
and infant birthweight on antibody responses to 
BOOSTRIX in pregnant women at time of delivery, and in their newborn infants at birth.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         17 
 • To assess maternal secretory immunity through 
measurement of breast milk antibodies to Tdap vaccine 
antigens in women at the time of delivery, at 6 weeks 
postpartum, at 10 weeks (in ½ of women) or 18 weeks (in ½ of women) postpartum, and at 6 months after delivery.  
• To assess the cytokine profile after stimulation in vitro with diphtheria, tetanus and pertussis antigens of peripheral blood mononuclear cells (PBMC) obtained from women before and one month after receiving 
BOOSTRIX or Td. 
• To assess the cytokine profile after stimulation in vitro 
with diphtheria, tetanus, and pertussis antigens of PBMC 
obtained from infants before the first dose of DTwP 
(approximately 6 weeks of age) in all subject s, one month 
after the first dose of DTwP (approximat ely 10 weeks of 
age) in ½ of infants, one month after the last dose of DTwP (approximately 18 weeks of age) in ½ of infants, 
and at 6 months of age in all infants.  
 
Outcome Measures:  
  
 
   
  
Primary:  
Safety and Tolerability:  
• Safety in pregnant women: Frequency and severity of study vaccine- related serious adverse events  (SAEs), and 
all SAEs  in pregnant women from study vaccination 
through 6 months postpartum, description and 
comparison between those receiving BOOSTRIX and Td. 
• Safety in pregnant women and fetuses/infants: Frequency and severity of adverse events specific to pregnancy, in pregnant women and their infants (as delineated in 
Section 9.2.4), description and comparison between those 
receiving BOOSTRIX and Td.  
• Tolerability in pregnant women: Frequency and severity 
of solicited injection site and systemic reactogenicity 
events fro m study vaccination until 7 days following 
vaccination (Day 8). 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         18 
 • Tolerability in pregnant women: Frequency and severity 
of all unsolicited non-serious AEs from day of study 
vaccination to Day 31, description and comparison 
between those receiving BOOSTRIX and Td.  
• Safety in the infants: Frequency and severity of study 
vaccine -related  serious adverse events , and all SAEs  in 
infants from birth  through 6 months of age, description 
and comparison between infants born to women vaccinated with BOOSTRIX and Td. 
Imm unogenicity: 
• Infant humoral immunity: Geometric Mean 
Concentration ( GMC ) of serum IgG antibodies to PT as 
measured by [CONTACT_301907] -Linked Immunosorbent Assay 
(ELISA ) at birth between infants born to women 
vaccinated with BOOSTRIX and Td. 
 Secondary:  
Immunogenicity:  
• Maternal humoral immunity: GMC of serum IgG antibodies to Tdap vaccine antigens (PT ( Pertussis 
Toxin ), FHA  (Filamentous Hemagglutinin ), PRN 
(Pertactin ), tetanus, diphtheria) as measured by [CONTACT_452368], at the time of delivery, and 6 months after 
delivery.  
• Infant humoral immunity: GMC of serum IgG antibodies 
to Tdap vaccine antigens (PT, FHA, PRN, tetanus, diphtheria) as measured by [CONTACT_452369] (approx imately 6 weeks of age) 
among infants born to women vaccinated with 
BOOSTRIX compared to Td.  
• Placental antibody transfer: The geometric mean ratio (GMR) of maternal and infant -specific Tdap -specific 
antibodies (PT, FHA, PRN, tetanus, diphtheria) as 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         19 
 measure d by [CONTACT_452370].  
• Interference with infant responses among infants whose 
mothers received intrapartum BOOSTRIX compared to 
Td: GMC of antibodies to DTwP vaccine antigens (PT, FHA, PRN, Fimbriae 2  (FIM2 ), Fimbriae 3 (FIM3 ), 
tetanus, diphtheria) as measured by [CONTACT_452371] (~10 weeks of age, ½ of infants), one month after the third dose of DTwP vaccine (~18 weeks of age, ½ of infants), and at 6 months of age. 
 Exploratory: Immunogenicity:  
• Maternal immunogenicity cofactors for maternal and 
neonatal anti -PT antibody responses following 
intrapartum BOOSTRIX: Maternal age (18 -29, 30-39 
years old), parity (primiparous vs. multiparous), GA at time of vaccination (14-17, 18-21, 22-26 weeks), GA at 
time of delivery (28 -32, 33-36, 37 or more weeks), and 
infant birthweight as potential independent associations with PT GMC.  
• Maternal secretory immunity: GMC of breast milk IgG and IgA antibodies to Tdap vaccine antigens (PT, FHA, PRN, tet anus, diphtheria) as measured by [CONTACT_452372], at 6 weeks after deliver, at 10 weeks (in ½ of women) or 18 weeks (in ½ of women) after delivery, and 6 months after delivery after intrapartum receipt of BOOSTRIX versus Td. 
• Maternal  cytokine responses: Cytokines produced by 
[CONTACT_452373], as measured by [CONTACT_423140], in women 
before and one month after receiving Tdap. Cytokines 
measured will include: Interferon ( IFN)-γ, Inerleukin 
(IL)- 10, IL -12p70, IL -12/IL -23p40, IL -13, IL -15, IL -16, 
IL-17A, IL -1α, IL-1β, IL-2, IL -4, IL -5, IL -6, IL -7, IL -8, 
Tumor Necrosis Factor ( TNF )-α, and TNF -β. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         20 
 • Infant cytokine responses: Cytokines produced by [CONTACT_452374], measured by [CONTACT_452375] (or umbilical cord blood), one month after the first dose of DTwP (~[ADDRESS_576707] s), one month after the last dose of study vaccine 
(approximately [ADDRESS_576708] s), and at 6 months 
of age. Cytokines measured will include: IFN -γ, IL-10, 
IL-12p70, IL -12/IL- 23p40, IL -13, IL -15, IL -16, IL -17A, 
IL-1α, IL-1β, IL-2, IL -4, IL -5, IL -6, IL -7, IL -8, TNF-α, 
and TNF-β. 
 
Description of Study Design:  This is a phase II, single center, randomized, double-blind, active-controlled study in which 200 healthy pregnant women, 
ages 18 through 39 years, inclusive, will be randomly allocated in a 2:1 ratio to receive either Tdap (BO OSTRIX ) or Td at 14 
0/7 weeks through 26 6/7 weeks estimated GA. After signing an informed consent form (ICF), all subject s will undergo a review 
of current and past medical history, current and prior medication use, and recent and relevant vaccination his tory. A physical 
examination performed as part of routine antenatal care or a study- specific focused exam may be used to determine 
eligibility. For the fetuses of pregnant subject s, GA will be 
established by [CONTACT_2207], whenever possible, in combination with date of last menstrual period (LMP), when available, and 
fundal height. Eligibility will be confirmed , and the subject  will be enrolled in 
the study. Each subject  will receive prenatal care consistent with 
national guidelines and with local standards as practiced by [CONTACT_452376]. In Mali, this includes hemoglobin, sickle cell test, 
Rh group, HIV, syphilis, toxoplasmosis, and rubella serology 
and urine glucose and protein at the first prese ntation for 
antenatal care, urine albumin and glucose at each subsequent 
visit and ultrasound at [ADDRESS_576709] specimens 
collected at birth, at 6 weeks after delivery, and at 6 months after delivery. In addition, women- infant pairs will be allocated in a 
1:[ADDRESS_576710] dose of DTwP (approximately 10 weeks of age), or at 
one month following the third dose of DTwP (approximately 18 
weeks of age). Thus, pregnant subject s will typi[INVESTIGATOR_44769] 7 
clinic visits (only [ADDRESS_576711] visit after 
vaccinati on, on Day 31): 3 antenatal visits (Screening Visit, 
Study Day 1, and Study Day 31, unless delivery occurs first), 1 
visit at the time of delivery, and 3 postpartum visits – at [ADDRESS_576712]  will also undergo 2 home visits 
after vaccination to assess her health status (Days 4 and 8).  
Infants born to the pregnant subject s will have 4 study visits: at 
birth, at approximately 6 weeks of age (day of first DTwP), at 
approximately 10 or 18 weeks of age (one month after first or third dose of DTwP, respectively), and at 6 months of age. Blood and colostrum/breast milk samples for immunologic 
assessments will be collected as described below:  
• Pregnant subject s: approximately 30 mL of whole blood 
will be collected by [CONTACT_452377] 1 (prior to vaccination), Study Day 31 (one month after 
vaccination), at delivery, and at 6 months postpartum in all women.  
• Infants: up to [ADDRESS_576713] blood will be 
collected at deli very and 5 mL peripheral blood will be 
collected by [CONTACT_452378] 6 weeks (prior to first dose 
of DTwP), either the 10-week or 18- week (per 
randomized study schedule), and [ADDRESS_576714] blood is preferred 
over venipuncture.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         22 
 • At delivery, and at the 6-week, either the 10- week or 18 -
week (per randomized study schedule), and the 6-month 
postpartum visit,  a [ADDRESS_576715] 4 days of life.  
Safety will be monitored from the time of signing of the ICF until trial termination.  
Estimated Time to Complete 
Enrollment:  Approximately [ADDRESS_576716]  
 
Table 1: Treatment Arms and Study Vaccine to be Administered 
 Treatment Arm  
Subject  Group  BOOSTRIX  Td Total  
Pregnant women [ADDRESS_576717] caused by 
[CONTACT_202448] (B. pertussis), a Gram -negative bacterium that lives in the upper respi[INVESTIGATOR_14921]. Pertussis is highly contagious. The bacteria attach to the cilia that line part of the upper respi[INVESTIGATOR_2133], and release toxins which damage the cilia and inflame the airways. While 
disease usually starts with cold -like symptoms and maybe a mild cough or fever, it may progress 
to paroxysms of coughing, post-tussive vomiting, and exhaustion. Pertussis is particularly 
dangerous in young infants, in whom it may lead to pneumonia, pulmonary hypertension, 
convulsions, apnea, encephalopathy, and death. 
2.1.2. Burden of Illness  
The introduction of pertussis vaccination in the past century has led to dramatic decreases in 
pertussis disease throughout the world. Nevertheless, pertussis burden remains high globally, as an estimated 16 million cases of pertussis occurred worldwide as recently as 2008.[ 1] Moreover, 
there has been a resurgence in pertussis disease in industrialized countries in recent years, with over 48,000 cases reported in the US alone for 2012.
 [2] This rise is likely due to a combination 
of factors, including improved diagnostics, heightened awareness of the disease, a decrease in 
natural immunity due to  low circulation, and decreased duration of protection from acellular 
pertussis vaccines. [3] 
Even in settings where vaccination coverage is high, the highest incidence of serious disease and 
mortality o ccurs in infants under two months of age, as they are too young to receive protection 
through current pertussis vaccines. In the US, this age group accounts for 57% of all infant pertussis hospi[INVESTIGATOR_602]. [ 4, 5] 
Less is known about pertussis in low resource settings.  A modeling study estimated there were 
[ADDRESS_576718] deaths occurring in developi[INVESTIGATOR_14696]. [ 1, 2, 6] Recent 
data from the Pneumonia Etiology Research for Child Health (PERCH) study, a case-control study of pneumonia etiology conducted in 7 low and middle resource countries, identified 
pertussis in 2.2% of severe pneumonia hospi[INVESTIGATOR_4355] 2.9% of pneumonia deaths. Younger, 
unimmunized, and HIV-exposed infants, and those in Africa, were most at risk. The case- fatality 
rate among infants 1 -5 months of age at the 5 African sites where cases were detected was 
12.5%. As PERCH excluded children younger than 1 month of age, these are undoubtedly 
underestimates. [7] 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         28 
 2.1.3. Prevention of Pertussis in Young Infants through Maternal Vaccination in 
Developed Countries  
Serious disease and death due to pertussis overwhelmingly occur in infants under two months of 
age, including in settings with excellent access to medical care and high vaccination coverage. [3] The rising incidence of pertussis in industrialized countries among infants too young to 
complete their primary vaccination series has prompted recommendations for pertussis vaccination during pregnancy in the US, [LOCATION_006], New Zealand, and several Latin Americ an and 
European countries. [ 1-4, 8]The goal of these recommendations is to achieve protection of young 
infants through transplacental transfer of maternal immunoglobulin G antibodies until active immunization of the infant can occur. The US Advisory Committee on Immunization Practices (ACIP ) first recommended antenatal pertussis immunization in 2011 for women who had not 
previously received Tdap vaccine, [ 9]and expanded this recommendation to all pregnant women 
during every pregnancy, regardless of prior receipt of Tdap. [10] In support of this policy, both 
observational [ 11, 12] and interventional [ 13] studies have shown that antenatal Tdap 
immuniz ation results in increased infant antibody levels. The benefits of this intervention were 
further supported through an evaluation of the national antenatal pertussis immunization program 
in the [LOCATION_006] begun in 2012, in which a case-control study design demonst rated a vaccine 
effectiveness of 91% against laboratory-confirmed clinical pertussis among children younger 
than 3 months of age. [14] In the US, a case control study estimated that maternal Tdap vaccine 
given in the third trimester of pregnancy was 77.7% effective against the outcome of pertussis in infants younger than 2 months of age. This estimate rose to 90.5% against hospi[INVESTIGATOR_452334]. [ 15] 
2.1.4. Interference of Maternal Antibody with Infant Immune Responses  
The beneficial effects of maternal antibody early in life must be balanced with any detrimental 
effects on primary infant responses to pertussis vaccines. In the maternal pertussis immunization 
studies from the 1930s and 1940s in the US, infant agglutinin antibody responses to whole- cell 
pertussis vaccine were lower in infants born to mothers who received whole- cell pertussis 
vaccine as compared to mothers who received no vaccine. Subsequent studies in the 1990s 
examining the effect of pre-existing antibodies in unvaccinated pregnant women showed that infant responses to whole- cell vaccines were suppressed by [CONTACT_094] -existing maternal antibody, while 
responses to acellular vaccines were not affected, or at least were suppressed to a lesser degree. 
[16-18] One of these studies [ 18]evaluated this issue within the NIAID -funded Multicenter 
Acellular Pertussis Trial (MAPT), which allowed direct comparison between whole- cell and 
multiple acellular pertussis vaccines. In this evaluation, pre -existing anti-PT antibodies had a 
strongly negative effect on PT responses for the two whole- cell DTwP vaccines, but only a 
minimal reduction for the acellular DTaP vaccines.  
Several recent studies in in the US, Europe, and Vietnam have described the immunogenicity of 
acellular pertussis vaccines in pregnancy, and in all cases the infants also received acellular 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         29 
 pertussis vaccines. [10, 19 -22] In all studies, the first dose of infant vaccine was given at or after 
2 months of age. An NIAID-sponsored study of Tdap vs. placebo in 48 women in the US found 
that Tdap was immunogenic in pregnant women and that infants born to such women had 
statistically higher concentrations of pertussis antibodies at delivery and 2 month s of age. 
Antibody titers for FHA at age 7 months were significantly lower in infants whose mothers 
received Tdap, although the difference was no longer significant at 13 months of age following a 
Tdap booster dose. [ 10] In a nonrandomized study in Belgium, pregnant women who received 
Tdap and their infants through [ADDRESS_576719] persisted for PT responses after the 
booster dose. [ 20] In Vietnam, women and infants up to 2 months of age had significantly higher 
GMCs for PT, PRN, and FHA.  One month after completion of the primary infant vaccination 
schedule, anti-PRN GMC was significantly lower in the vaccinated group. [ 19] In the US, the 
blunting of infant responses to FHA was overcome by [CONTACT_452379]; 
studies in Vietnam are on -going to determine the effect of the booster dose on infant responses. 
[10, 19, 20] 
The clinical significance of any blunting effect of maternal antibody on infant primary responses is complicated by [CONTACT_452380] s. High concentrations 
of antibodies to PT, FHA, PRN, Fim 2, and Fim [ADDRESS_576720] disease. 
Small amounts of antibody to the A subunit of PT will prevent death in infants although it will not prevent infection. [ 22] Therefore, while all responses may be clini cally important, the 
postulated critical role of anti- PT antibodies in protection against severe infant pertussis justifies 
an emphasis on this response in the first months of life. 
2.1.5. Cytokines Produced in Response to Vaccine Antigens  
The development of robust antibody responses relies on the stimulation of T cells, which 
supports antibody development through direct interactions with B lymphocytes and the secretion 
of cytokines. Th1 and Th17 cytokines have been shown to contribute to pr otection against 
pertussis in mice, following infection or vaccination. [ 23] Most recently, IL -17 induced by 
[CONTACT_452381]. [ 24] There is 
limited information on cytokine T cell responses to Tdap during pregnancy. A recent study reported transient and impaired IFN-γ responses in pregnant women who received Tdap, [ 25] but 
these res ults were derived from a very small number of subjects and using whole blood (as 
opposed to purified cells) stimulated with polyclonal, not pertussis- specific antigens. It is 
possible that the passive transfer of maternal antibodies might interfere with the ability of pertussis antigens to elicit protective cellular responses. Cytokine measurements in vaccinated infants would allow assessment of the potential impact of maternal immunization on the infant’s 
T cell responses following vaccination. 
DMID Protocol 16- [ADDRESS_576721] feeding has been associated with reduced risk of respi[INVESTIGATOR_452335]. [26, 27] 
Pertussis- specific IgA and IgG have been detected in breast milk from women who had received 
DTwP during childhood [ 28]as well as IgA in colostrum of Tdap vaccinated pregnant 
women [29, 30], and it has been proposed that breastfeeding may have a protective role against 
infection. [ 28, 29] Investigating antibodies in breast milk of Tdap vaccinated women will 
provide a more comprehensive evaluation of immunogenicity and test the hypothesis that women 
vaccinated during pregnancy develop mucosal antibodies that are also available for protection of 
the offspring. Studies that have examined the effect of maternal antibodies on infant responses to acellular pertussis vaccines have not investigated antibodies in maternal milk. [9, 10 ] 
2.1.7. Pertussis Vaccines in Pregnant Women  
In Mali, there are no recommendations for vaccinating pregnant women routinely with a 
pertussis-containing vaccine. In the US, the [LOCATION_006], and elsewhere, both Adacel and BOOSTRI X 
are licensed. Adacel is a pregnancy category C and BOOSTRIX is a pregnancy category B. The 
US and [LOCATION_006] recommend that either vaccine be given to pregnant women. Only BOOSTRIX is pre-qualified by [CONTACT_14300], and therefore is the vaccine of choice for developi[INVESTIGATOR_14696], and 
the vaccine that will be used for this study. [ 14] Standa rd of care in Mali is to administer to 
pregnant women at the first prenatal visit a dose of Td vaccine manufactured by [CONTACT_452382] E. Limited  and prequalified by [CONTACT_14300].  The whole- cell vaccines received by [CONTACT_452383], with most low- income countries using a pentavalent vaccine (DTwP -HepB -Hib) 
manufactured by [CONTACT_127958] 8 different WHO- prequalified manufacturers.  [14] 
In the [LOCATION_002], post licensure surveillance data of Tdap during pregnancy, including studies looking at repeated doses, have revealed no association with medically attended acute adverse 
events during pregnancy or adverse birth outcomes. [ 1-4] A recent review of 392 reports to the 
Vaccine Adverse Event Reporting System ( VAERS ) of AEs in pregnant women who received 
Tdap vaccine after the routine recommendation (11/01/2011–6/30/2015) was compared to published data before the routine Tdap recommendation (01/01/2005–06/30/2010). An incr ease 
in proportion of reports for stillbirths (1.5–2.8%) and injection site reactions/arm pain (4.5–
11.9%) and a decrease in reports of spontaneous abortion (16.7–1%) occurred after the recommendation compared to the period before the routine recommendation for Tdap during 
pregnancy. In most recent reports, vaccination (79%) occurred during the third trimester. 
Overall, no new or unexpected AEs were noted among pregnant women who received Tdap after routine recommendations for maternal Tdap vaccination. Changes in reporting patterns would be 
expected, given the broader use of Tdap in pregnant women in the third trimester after the 
routine recommendation as compared to before. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         31 
 2.1.8. Timing of Maternal Immunization 
In the US, the ACIP states that the optimal timing for Tdap administration is between 27 and 36 
weeks gestation although Tdap may be given at any time during pregnancy. [ 10] Two recent 
studies support that earlier vaccination may be more beneficial. In Israel, a prospective study that 
included women in their 20th week of pregnancy or later demonstrated that IgG GMCs to PT 
were higher in newborn cord sera when women were immunized at 27-30 weeks compared with 
31-36 weeks of gestation. [ 20] Likewise, in a prospective observation cohort study in Geneva, 
Switzerland, early second -trimester maternal Tdap immunization significantly increased neonatal 
antibodies compared to later dosing. [ 21] 
In Mali, and elsewhere in Africa, tetanus -containing vaccines are recommended to  be given at 
the first pregnancy encounter. The rationale for this recommendation is that many women in 
Mali will not present for multiple, regular prenatal visits, as is done in the [LOCATION_002]. Thus, 
the recommendation for first encounter vaccination e nsures that a woman receives the vaccine 
and has adequate time to develop immunity and transfer antibody to her unborn child. Delaying the administration of tetanus -containing vaccines until the third trimester of pregnancy would be 
a deviation from standard of care, and would likely be unacceptable to the community. Therefore, second trimester vaccination may be the best option in this trial for consistency with local practices. Any pregnant women who presents in the first trimester and wishes to participa te 
in the study will be asked to return during the second trimester for randomization and receipt of a tetanus -containing vaccine.  
2.2. Rationale  
Unfortunately, the positive impact of maternal pertussis vaccination cannot be assumed to be 
generalizable to low resource settings, where most pertussis deaths occur. Maternal antibody 
transfer in low resource settings may be adversely affected by [CONTACT_87734], HIV, malaria, and other factors. [ 12] In addition any diminution of primary infant antibody responses by [CONTACT_452384]. First, infants in Africa and many low resource countries in Asia receive their primary pertussis- containing vaccines at earlier time points – 6, 10, and, [ADDRESS_576722] low resource countries do not include a pertussis booster in the second year of life. [ 1, 10] The second reason that interference with infant 
immunization may be more pronounced in developi[INVESTIGATOR_452336]- cell vaccines in the primary in fant series. As above, prior studies suggest that higher 
levels of maternal antibodies were associated with lower infant responses to whole- cell pertussis 
DMID Protocol 16- [ADDRESS_576723] seen in infants given acellular pertussis vaccines. [13] These two 
factors highlight the need for context- specific data on maternal pertussis immunization.  
Maternal pertussis vaccination would be feasible in low resource countries. Exist ing antenatal 
tetanus immunization programs have been successful worldwide and may serve as a platform for 
pertussis vaccine introduction as Tdap combinations could be substituted for Td or tetanus toxoid (TT). In Mali, standard of care is to administer Td to pregnant women during their first contact 
[CONTACT_85595], which for most women is in the second trimester.  
Realizing the importance of pertussis prevention in infants too young to receive vaccine, and the lack of data on the impact of mate rnal vaccination on infant responses in developi[INVESTIGATOR_452337]- cell vaccines are used, a study is necessary to examine the safety, 
immunogenicity, and effect on infant antibody responses of a Tdap vaccine administered during pregnancy amon g women in Mali.  
2.3. Potential Risks and Benefits  
2.3.1. Potential Risks and Discomforts 
The potential risks of participating in this study are those associated with having blood drawn, 
intramuscular (IM) injection of and possible reactions to the study vaccine, accompanying risks 
to the fetus and infant of the vaccinated mother, risks of breast milk collection, and breach of confidentiality.  
Ultrasound : All women will have an ultrasound to date the pregnancy. This procedure is not 
harmful to the mother or fetus, but it may feel uncomfortable. Mothers will be informed if the ultrasound reveals any implications for the pregnancy or the health of the child. It is possible this 
news may cause emotional distress; there may also be additional costs to women who choose to 
perform further testing based on this information. Phlebotomy:   Drawing blood is typi[INVESTIGATOR_452338]. However, it often causes 
transient mild discomfort. Some subject s may have near syncope (2%) or true syncope (fainting). 
Fainting is a transient autonomic (vasovagal) response to phlebotomy that occurs in 
approximately 1% of blood donors and less than 1% of those having diagnostic phlebotomy. [ 24] 
It is managed by [CONTACT_452385], loosening his or her clothes, monitoring vital signs, 
reassuring the subject, and giving fluids. Minor bruising (up to 12%) or a hematoma (2- 3%) may 
occur at the blood draw site. It can be prevented or decreased in frequency by [CONTACT_452386], when it occurs, by [CONTACT_452387]. Rarely, following phlebotomy, persons may have nerve injury (typi[INVESTIGATOR_452339]) causing pain, paresthesias, and motor or sensory loss. This 
phenomenon is uncommon and typi[INVESTIGATOR_452340]. [ 25] 
Infection at the site of the blood draw is rare, and can be avoided by [CONTACT_452388]. In a study of over 4000 persons undergoing routine venipuncture for 
insurance application, there were no serious local reactions such as cellulitis or phlebitis. [ 24] 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         33 
 Intramuscular Injection:  The injection of a vaccine into the deltoid muscle, as will be done in 
this study, is typi[INVESTIGATOR_247706]. However, it often causes transient discomfort. As with 
phlebotomy, although less commonly, it can cause near syncope or syncope. It can also cause an 
abscess, a hematoma, injury to blood vessels and peripheral nerves, or tingling or numbness. 
Proper technique reduces the risks of infection, bleeding, and injury. The Vaccine:   BOOSTRIX
 manufactured by [CONTACT_23983], is indicated for active booster immunization 
against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single intramuscular injection for persons aged 10 years of age and older in the US.
  [31] 
The safety of BOOSTRIX has been evaluated in multiple studies in adolescents and adults. The most relevant to this age group was a study in US adults 19 to 64 years of age that compared 
BOOSTRIX (n=1,522) to Adacel ([COMPANY_011] Pasteur) (n=762). Solicited local and systemic 
reactions were monitored for 14 days after vaccination, and medically significant AEs and SAEs for 6 months. Solicited adverse reactions (any/severe), reported by [CONTACT_452389][INVESTIGATOR_452341] (61 %/1.6%), erythema (21%/1.6%), induration (17.6%/1.4%), 
headache (30%/2.2%), fatigue (28.1%/2.5%), any gastrointestinal symptoms (15.9%/1.2%), and fever (5.5% >99.5
oF/0.1% >102.2oF). The reactogenicity profile closely mirrored that of Adacel, 
the other US l icensed Tdap.  [31] 
The incidence of unsolicited adverse events reported in the 31 days after vaccination was comparable in the 2 groups (17.8% and 22.2% for BOOSTRIX and Adacel).  Serious adverse events were reported to occur during the entire study period (0-6 months) by 1.4% and 1.7% of subjects who received BOOSTRIX and Adacel. During the 6-month extended safety period, no 
serious adverse events of a neuroinflammatory nature or with information suggesting an 
autoimmune etiology were reported in subjects who received BOOSTRIX. [ 31] 
Since licensure, additional events have been voluntarily reported, but none have prompted 
concern for c ommon or severe events caused by [CONTACT_29500].  
Rare or uncommon reactions include anaphylaxis or other acute allergic reactions and syncope. 
Acute and potentially life -threatening allergic reactions (i.e., anaphylaxis) are also possible. 
These reactions occur in about [ADDRESS_576724] as skin rash (urticaria), swelling around the mouth, throat or eyes (angioedema), 
difficulty breathing (bronchospasm), a fast pulse (tachycardia), or decrease in blood pres sure 
(hypotension). If these reactions occur, they can usually be stopped by [CONTACT_452390]. As with any vaccine or medication, there is a 
very small chance of a fatal reaction (death), although researche rs do not expect this to occur. 
[31] 
If Guillain -Barré syndrome (G BS) occurred within 6 weeks of receipt of a prior vaccine 
containing tetanus toxoid, the risk of Guillain- Barré syndrome may be increased following a 
subsequent dose of tetanus toxoid-containing vaccine, including BOOSTRIX. A review by [CONTACT_452391] 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         34 
 Institute of Med icine (IOM) found evidence for a causal relationship between receipt of tetanus 
toxoid and both brachial neuritis and Guillain-Barré syndrome. [ 31] 
Progressive or unstable neurologic conditions ( e.g., cerebrovascular events and acute 
encephalopathic conditions) are reasons to defer vaccination with a pertussis -containing vaccine, 
including BOOSTRIX. It is not known whether administration of BOOSTRIX to persons with an 
unstable or progressive neurologic disorder might hasten manifestations of the disorder or affect 
the prognosis. Administration of BOOSTRIX to persons with an unstable or progressive 
neurologic disorder may result in diagnostic confusion between manifestations of the underlying illness and possible adverse effects of vaccination. [ 31] 
The vaccine manufacturer maintains a surveillance registry to collect data on pregnancy 
outcomes and newborn health status outcomes following vaccination with BOOSTRIX during 
pregnancy. In the event of an observed safety signal from that registry, the manufacturer would share that information with the sponsor and appropriate actions for trial subject s would be taken. 
It is unknown if the vaccine to be used in this study poses any risks to an unborn child or to 
children born to mothers who are vaccinated during pregnancy. The vaccine is currently deemed 
as pregnancy category B. A developmental toxicity study has been pe rformed in female rats at a 
dose approximately 40 times the human dose (on a mL/kg basis) and revealed no evidence of 
harm to the fetus due to BOOSTRIX. Animal fertility studies have not been conducted with 
BOOSTRIX.  
The effects of the vaccine on lactation  and nursing, as well as the effects on the breastfed infant 
of a woman vaccinated with BOOSTRIX during pregnancy, are unknown. 
Breast Milk Collection:   Women will provide breast milk within the 4 days following delivery 
and at 3 time points postpartum (at 6 weeks, either 10 or 18 weeks, and 6 months postpartum). 
There is no significant risk of this collection. Some women may experience mild tenderness from 
milk expression. 
Potential Risks to Infants:  As with the risks to pregnant women, there is a possibi lity that 
obtaining a blood sample from your infant may cause some pain, swelling, bruising, or infection at the site of the blood draw. To avoid infection, a qualified and trained staff member will collect 
the blood from the infant.   
The standard of care in Mali is to vaccinate infants with the pentavalent Diphtheria and Tetanus and Pertussis and Haemophilus influenzae and Hepatitis B vaccine at 6, 10, and 14 weeks of age; 
this vaccinati on should provide protection. There is a possibility that the infant’s response to the 
pertussis vaccine could be lower after the usual infant vaccinations because of the mother’s study 
vaccine.  
Privacy and Confidentiality:   Subject s will be asked to provide and allow research team 
members access to personal/protect ed health information (PHI) of the woman and her infant . All 
attempts will be made to keep this PHI confidential within the limits of the law. However, there is a chance that unauthorized persons will see subject  PHI. All paper records will be kept in a 
DMID Protocol 16- [ADDRESS_576725] and/or copy research records maintained at the participating site 
for quality assurance and data analysis includ e groups such as the National Institute of Allergy 
and Infectious Diseases (NIAID) and/or its representatives and the US Food and Drug Administration (FDA). They also include the Malian Research Ethics Committee of the School 
of Medicine, Pharmacy, and Dentistry and the Malian National Drug Authority. 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov , as required 
by [CONTACT_20008]. This web site will not include information that can identify subject s. At most, this 
web site will include a summary of the results.  
There may be other unknown risks, discomforts, or side effects. 
2.3.2. Potential Benefits  
BOOSTRIX is licensed in the US for use in persons [ADDRESS_576726] s, their infants may receive the benefit of transplacental pertussis antibody 
transfer and/or b reast milk antibodies. These antibodies could potentially provide complete or 
partial protection against pertussis. Contacts of subject s, including infants, could benefit by [CONTACT_452392] a r esult cannot spread 
pertussis to their contacts. In summary, the prospect of direct benefit due to participation in this 
study exists for pregnant subject s and their fetuses/infants.   
There may be no direct personal benefit of participation. There is pote ntial that BOOSTRIX 
administered to pregnant women may cause harm in the infants if primary responses to pertussis-
containing vaccines are adversely affected. The potential societal benefit is that BOOSTRIX may 
be found to be safe, well tolerated, and immunogenic in pregnant women and lead to levels of 
antibodies in infants thought to protect them, thus informing scientists and policymakers on the benefits of Tdap for pregnant women and their babies in Mali and other African countries.  
Close follow-up of pregnant subject s, and infants will potentially afford them additional benefit 
due to frequent access to experts in obstetrics, pediatrics, and immunizations. Pregnant women 
enrolled in this study will receive an ultrasound, which is standard of care in Mali, but unaffordable to the majority. Likewise, pregnant women will receive the recommended set of 
pregnancy blood tests (glucose, syphilis, toxoplasmosis, HIV serologies) in Mali at no additional 
DMID Protocol 16- [ADDRESS_576727] 
forego these tests.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         37 
 3. OBJECTIVES  AND OUTCOME MEASURES  
3.1. Study Objectives  
3.1.1. Primary  
Safety and Tolerability : 
• To assess the safety and tolerability of a single 0.5 mL intramuscular injection of 
BOOSTRIX in pregnant women. 
• To assess the safety of a single maternal BOOSTRIX vaccination on the fetus and infant.  
Immunogenicity:  
• To assess the level of PT antibody at birth among infants whose mothers received a 
single dose of BOOSTRIX or Td while pregnant.  
3.1.2. Secondary  
Immunogenicity : 
• To assess the antibody response to BOOSTRIX vaccine antigens in pregnant women one 
month after receipt of BOOSTRIX, at the time of delivery, and at 6 months after delivery. 
• To compare the antibody levels of BOOSTRIX vaccine antigens at birth (cord blood) and 
6 weeks of age (before receiving any infant doses of Diphtheria, Tetanus, and whole- cell 
Pertussis ( DTwP) ) in infants whose mothers received BOOSTRIX or Td during 
pregnancy. 
• To assess placental antibody transfer by [CONTACT_452393] -specific antibody responses at delivery.  
• To assess interference with infant antibody responses to DTwP either prior to the second dose of the primary DTwP series, at approximately 10 weeks of age (in ½ of subject s), or 
approximately one month after the third dose of the primary DTwP series, at 
approximately 18 weeks of age (in ½ of subject s), and at 6 months of age (all subject s). 
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         38 
 3.1.3. Exploratory 
Immunogenicity : 
• To assess the effects of maternal age, parity, gestational age (GA) at which the vaccine is 
given, GA at delivery, and infant birthweight on antibody responses to BOOSTRIX in pregnant women at time of delivery, and in their newborn infants at birth. 
• To assess maternal secretory immunity through measurement of breast milk antibodies to Tdap vaccine antigens in women at the time of delivery, at 6 weeks postpartum, at 10 
weeks (in ½ of women) or 18 weeks (in ½ of women) postpartum, and at 6 months after delivery.  
• To assess the cytokine profile after stimulation in vitro with diphtheria, tetan us and 
pertussis antigens of peripheral blood mononuclear cells (PBMC) obtained from women before and one month after receiving Tdap or Td. 
• To assess the cytokine profile after stimulation in vitro with diphtheria, tetanus, and pertussis antigens of PBMC o btained from infants before the first dose of DTwP 
(approximately 6 weeks of age) in all subject s, one month after the first dose of DTwP 
(approximately 10 weeks of age) in ½ of infants, one month after the last dose of DTwP 
(approximately 18 weeks of age) in ½ of infants, and at 6 months of age in all infants. 
3.2. Study Outcome Measures  
3.2.1. Primary  
Safety and Tolerability:  
• Safety in pregnant women: Frequency and severity of study vaccine- related serious 
adverse events (SAEs ), and all SAEs in pregnant women from study vaccination through 
6 months postpartum, description and comparison between those receiving BOOSTRIX 
and Td. 
• Safety in pregnant women and fetuses/infants: Frequency and severity of adverse events 
specific to pregnancy, in pregnant women and their infants (as delineated in Section 
9.2.4), description and comparison between those receiving BOOSTRIX and Td. 
• Tolerability in pregnant women: Frequency and severity of solicited injection site and 
systemic reactogenicity events from study vaccination until 7 days following vaccination 
(Day 8).  
• Tolerability in pregnant women: Frequency and severity of all unsolicited non-
serious AEs from day of study vaccination to Day 31, description and comparison 
between those receiving BOOSTRIX and Td.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         39 
 • Safety in the infants: Frequency and severity of study vaccine- related  serious adverse 
events , and all SAEs  in infants from birth  through 6 months of age, description and 
comparison between infants born to women vaccinated with BOOSTRIX and Td. 
Immunogenicity:  
• Infant humoral immunity: Geometric Mean Concentration ( GMC ) of serum IgG 
antibodies to PT as measured by [CONTACT_301907] -Linked Immunosorbent Assay (E LISA ) at birth 
between infants born to women vaccinated with BOOSTRIX and Td.  
3.2.2. Secondary  
Immunogenicity:  
• Maternal humoral immunity: GMC of serum IgG antibodies to Tdap vaccine antigens 
(PT (Pertussis Toxin ), FHA  (Filamentous Hemagglutinin ), PRN ( Pertactin ), tetanus, 
diphtheria) as measured by [CONTACT_452394], at the time of delivery, and 6 months after delivery.  
• Infant humoral immunity: GMC of serum IgG antibodies to Tdap vaccine antigens (PT, 
FHA, PRN, tetan us, diphtheria) as measured by [CONTACT_452395] (approximately 6 weeks of age) among infants born to women vaccinated 
with BOOSTRIX compared to Td.  
• Placental antibody transfer: The geometric mean ratio (GMR) of maternal and  infant-
specific Tdap -specific antibodies (PT, FHA, PRN, tetanus, diphtheria) as measured by 
[CONTACT_452396].  
• Interference with infant responses among infants whose mothers received intrapartum 
BOOSTRIX com pared to Td: GMC of antibodies to DTwP vaccine antigens (PT, FHA, 
PRN, Fimbriae 2  (FIM2 ), Fimbriae 3 (FIM3 ), tetanus, diphtheria) as measured by [CONTACT_452397] (~10 weeks of age, ½ of infants), one month after the third dose of DTwP vaccine (~18 weeks of age, ½ of infants), and at 6 months of age.  
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         40 
 3.2.3. Exploratory 
Immunogenicity:  
• Maternal immunogenicity cofactors for maternal and neonatal anti -PT antibody responses 
following intrapartum BOOSTRIX: Maternal age (18 -29, 30-39 years old), parity 
(primiparous vs. multiparous), GA at time of vaccination (14-17, 18-21, 22-26 weeks), 
GA at time of delivery (28 -32, 33-36, 37 or more weeks), and infant birthweight as 
potential independent associations with PT GMC. 
• Maternal secretory immunity : GMC of breast milk IgG and IgA antibodies to Tdap 
vaccine antigens (PT, FHA, PRN, tetanus, diphtheria) as measured by [CONTACT_452398], at 6 weeks after deliver, at 10 weeks (in ½ of women) or 18 weeks 
(in ½ of women) after delivery, and 6 months after delivery after intrapartum receipt of 
BOOSTRIX versus Td.  
• Maternal cytokine responses: Cytokines produced by [CONTACT_452373], as measured by [CONTACT_423140], in women before and one month a fter receiving Tdap. Cytokines measured will include: Interferon ( IFN)-γ, 
Inerleukin ( IL)-10, IL -12p70, IL -12/IL- 23p40, IL -13, IL -15, IL -16, IL -17A, IL -1α, IL-
1β, IL-2, IL -4, IL -5, IL -6, IL -7, IL -8, Tumor Necrosis Factor ( TNF )-α, and TNF -β. 
• Infant cytokine responses: Cytokines produced by [CONTACT_452399], measured by [CONTACT_452400] (or umbilical cord blood), 
one month after the first dose of DTwP (~10 weeks of age, ½ of subjects), one month after the last dose of study vaccine (approximately 18 weeks, ½ of subjects), and at 6 months of age. Cytokines measured will include: IFN -γ, IL-10, IL -12p70, IL -12/IL-
23p40, IL -13, IL -15, IL -16, IL -17A, IL -1α, IL-1β, IL-2, IL -4, IL -5, IL -6, IL -7, IL -8, 
TNF -α, and TNF-β.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         41 
 4. STUDY DESIGN  
This is a phase II, single center, randomized, double-blind, active-controlled study in which 200 
healthy pregnant women , ages 18 through 39 years, inclusive, will be randomly allocated in a 2:1 
ratio to receive either Tdap (BOOSTRIX ) or Td at 14 0/7 weeks through 26 6/7 weeks estimated 
GA. After signing an informed consent form (ICF), all subject s will undergo a review of current 
and past medical  history, current and prior medication use, and recent vaccination history. A 
physical examination performed as part of routine antenatal care or a study -specific brief exam 
may be used to determine eligibility. For the fetuses of pregnant subject s, GA wil l be established 
by [CONTACT_2207], whenever possible, in combination with date of last menstrual period (LMP), when available, and fundal height. 
Eligibility will be confirmed , and the subject  will be enrolled in the study. Each subject  will 
receive prenatal care consistent with national guidelines and with local standards as practiced by 
[CONTACT_452401]. In Mali, this 
includes hemoglobin, sickle cell test, Rh group , HIV, syphilis, toxoplasmosis, and rubella 
serology and urine glucose and protein at the first presentation for antenatal care, urine albumin and glucose at each subsequent visit and ultrasound at [ADDRESS_576728] specimens 
collected at birth, at 6 weeks after delivery, and at 6 months after delivery.  In addition, women-infant pairs will be allocated in a  1:[ADDRESS_576729] dose of DTwP (approximately 10 weeks of age), or at one month following the third 
dose of DTwP (approximately 18 weeks of age). Thus, pregnant subjects will typi[INVESTIGATOR_44769] 7 
clinic visits (only [ADDRESS_576730] visit after vaccination, on Day 31): 3 antenatal visits (Screening Visit, Study Day [ADDRESS_576731]), 1 
visit at the time of delivery, and 3 postpartum visits – at [ADDRESS_576732]  will also undergo 2 home visits after 
vaccination to assess her health status (Days 4 and 8).  
Infants born to the pregnant subject s will have 4 study visits: at birth,  at approximately 6 weeks 
of age (day of first DTwP), at approximately 10 or 18 weeks of age (one month after first or third 
dose of DTwP, respectively), and at 6 months of age. Blood and colostrum/breast milk samples for immunologic assessments will be collected as 
described below:  
• Pregnant subject : approximately 30 mL of blood will be collected on Study Day 1 (prior 
to vaccination), Study Day 31 (one month after vaccination), at delivery, and at 6 months postpartum in all women. 
• Infants: up to [ADDRESS_576733] blood will be collected at delivery and 5 mL peripheral blood will be collected at 6 weeks (prior to first dose of DTwP), either the 10-
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         42 
 week or 18-week (per randomized study schedule), and [ADDRESS_576734] blood is 
preferred over venipuncture.  
• At delivery, and at the 6-week, either the 10- week or 18 -week (per randomized s tudy 
schedule), and the 6-month postpartum visit, a 10-20mL sample of colostrum or breast 
milk will be collected. When possible, the first breast milk or colostrum collection will 
occur while the mother and baby [CONTACT_452402]. When not possible, it may be collected any time within the first 4 days of life.  
Safety will be monitored from the time of signing of the ICF until trial termination.  
For additional details on study procedures and evaluations and study schedule by [CONTACT_452403]/days, see Sections [ADDRESS_576735] Inclusion/Exclusion Criteria in DMID-sponsored studies. Questions about eligibility will be directed toward the DMID Medical Officer.  
5.1. Subject Inclusion Criteria  
Prospective subject s must meet all of the following inclusion criteria to be considered eligible for 
enrollment: 
1. Healthy pregnant w oman 18-39 years of age, inclusive. 
2. Singleton fetus, with estimated gestational age of 14 0/7 through 26 6/[ADDRESS_576736] 180 days. Any prescription change that is due to change of health care provider, insurance company, etc., or that is done for financial reasons, as long as in the same class of medication, will not be considered a deviation 
of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by [CONTACT_369593] [INVESTIGATOR_29353] -investigator, will not be considered a deviation of this inclusion criterion. Subjects 
may be on chronic or as needed (prn) medications if, in the opi[INVESTIGATOR_29352]-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immu nogenicity and do not 
indicate a worsening of medical diagnosis or condition. Similarly, medication changes subsequent to enrollment and the study vaccination are acceptable provided the subject is asymptomatic, condition stable, and there is no additional  risk to the subject or 
interference with the evaluation of responses to the study vaccination.  
 
3 Physical examination performed as part of routine antenatal care of a study -specific brief exam may be used to determine 
eligibility.                                                                                                                 
4 Oral temperature less than 37.8°C.                                                                                                                         
[ADDRESS_576737] not meet any of the following exclusion criteria to be considered 
eligible for enrollment:  
1. History of illness or an ongoing illness that, in the opi[INVESTIGATOR_871], may pose additional risk to the subject  or her fetus if she participates in the study. 
2. Infection requiring systemic antibiotics or antiviral treatment within the 7 days prior to study vaccination.  
3. Fever (oral temperature ≥ 37.8°C/100.0°F) or other acute illness within 3 days prior to study 
vaccination.
7  
4. Known active neoplastic disease8, anticancer chemotherapy, or radiation therapy (cytotoxic) 
within  3 years prior to study vaccination.  
5. History of any hematologic malignancy at any time.  
6. A history of a serious adverse event following previous immunizations (e.g., Bell’s Palsy, 
Guillain -Barre Syndrome, encephalopathy), or history of progressive neurologic disorders. 
7. Known or suspected disease that impairs the immune system including known or suspected HIV infection or HIV- related disease.  
8. Receipt of immunosuppressive therapy.
[ADDRESS_576738]. 
                                                 
7 An a cute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opi[INVESTIGATOR_452342]-investigator, the residual symptoms will not interfere with the ability to assess safety  
parameters as required by [CONTACT_760].  
8 excluding non-melanoma skin cancer.  
9 including long -term use of glucocorticoids: oral, inhaled, intranasal or parenteral prednisone ≥ 20 mg/day or equivalent for 
more than [ADDRESS_576739] ’s ability to participate in the trial.  
11. Have a history of alcohol or drug abuse within 5 years prior to study vaccination.11 
12. Known hypersensitivity or allergy to any component of the study vaccine (formaldehyde, 
alum).  
13. History of severe allergic reaction (e.g., an aphylaxis) after a previous dose of BOOSTRIX or 
any other vaccine directed against tetanus, diphtheria, or pertussis. 
14. Receipt or planned receipt of any live licensed vaccine within 30 days before or after vaccination or any inactivated licensed vaccine wit hin 14 days before or after vaccination. 
15. Receipt of immunoglobulin (except RhoGAM, which is allowed) or other blood products 
within 90 days prior to study vaccination. 
16. Receipt of an experimental agent or device within 30 days prior to vaccination, or the 
expected receipt of an experimental agent
12 (other than BOOSTRIX) during this trial-
reporting period.  
17. High risk for serious obstetrical complication (refer to ACOG Practice Bulletins for definitions, as necessary).
13 
18. Pregnant with a fetus with a known or sus pected major congenital14 anomaly or genetic 
abnormality.  
19. Study personnel or immediate family members (brother, sister, child, parent) or the spouse of study personnel. 
                                                 
[ADDRESS_576740]’s ability to participate in the study.  
[ADDRESS_576741] in a clinical trial, within 30 days prior to vaccination or who are expecting to enroll in such a  trial 
during the study period will also be excluded. Observational studies, surveys, and other studies that do not involve experim ental 
agents or devices are allowed.  
13 including the following: (a)gestational hypertension (well controlled history of essential or gestational hypertension, as 
evidenced by [CONTACT_452404], is allowed), (b)gestational diabetes not controlled by [CONTACT_452405] (the use of 
insulin or glyburide to control gDM, at the time of enrollment, is exclusionary), (c)current pre -eclampsia or eclampsia, (d)known 
current multiple gestation, (e)history of preterm delivery before EGA 35 weeks 0 days or current preterm labor, and/or (f)known 
intrauterine fetal growth restriction (defined as ultrasound confirmation of an estimated fetal weight that is less than the 10th 
percentile for gestational age).  
14 Congenital anomalies and definitions of major congenital  anomalies are discussed in detail in Section 9.1 under Assessment of 
Safety.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         46 
 5.3. Treatment Assignment Procedures  
5.3.1. Randomization Procedures  
Per International Council for Harmonisation (ICH) guideline E6: Good Clinical Practice (GCP), 
screening records will be kept at each participating VTEU site to document the reason why an 
individual was screened, but failed trial entry criteria. The reasons why individuals failed 
screen ing will be recorded in the Data Coordinating Center’s (DCC) Advantage eClinicalSM 
(Electronic Data Capture System).  
Once consented and upon entry of demographic data and confirmation of eligibility for this trial, 
the subject  will be enrolled. Pregnant su bject s will be randomly allocated to 1 of 2 treatment 
arms; [ADDRESS_576742]. 
At the time of enrollment subjects will also be assigned a study schedule. Women will be randomized in a 1:[ADDRESS_576743] specimen collection after delivery/birth for mother/infant pairs at either one month following the first dose of DTwP (approxim ately 10 weeks of age) or 
one month following the third dose of DTwP (approximately 18 weeks of age). When internet access allows, enrollment and randomization of subjects will be done online using the enrollment module of Advantage eClinical. A back-up randomization process will be in place in the event internet access is unavailable. The randomization schemes for assignment to 
treatment arm and assignment to study schedule will be prepared by [CONTACT_452406]. Advantage eClinical will assign each subject to a treatment arm and study schedule after the demographic and eligibility data have been entered 
into the system. Instructions for use of the enrollment module are included in the Advantage 
eClinical User’s Guide. A designated individual or individuals at each participating VTEU site 
will be provided with a treatment code list for emergency unblinding purposes, which will be kept in a secure place.  
Subject s who sign the informed consent form and are randomized but do not receive study 
vaccine may be replaced. Subject s who sign the informed consent form and are randomized and 
vaccinated, and subsequently withdraw or are withdrawn or terminated from this trial or are lost 
to follow-up, will not be replaced.  
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         47 
 The randomization scheme for this trial is presented in Table 1 . 
Table 1: Treatment Arm s and Study Vaccine to be Administered 
 Treatment Arm  
 
Subject Group  
 BOOSTRIX  Td  
Total 
Pregnant women [ADDRESS_576744] s, investigators, study personnel performing any 
study-related assessments following study vaccine administration, and laboratory personnel 
performing antibody assays will be blinded to treatment assignments.  
The randomization scheme will be generated by [CONTACT_452407] (i.e., research pharmacists or other trained/delegated personnel performing study 
vaccination preparations and unblinded study vaccine administrators) at each participating 
VTEU site  or subcontract ed site. 
The unblinded study vaccine administrator is a study personnel member credentialed to 
administer vaccines and may also participate in dose preparation but  will not be involved in 
study- related assessments or have subject contact [CONTACT_202406], for pregnant women or their infants. 
Data and Safety Monitoring Board (DSMB) may receive data in aggregate and presented b y 
treatment arm (pregnant women, infants). The DSMB may also be provided with expected and observed rates of the solicited AEs in an unblinded fashion and may request the treatment assignment be unblinded for an individual subject  if required for safety as sessment. In the open 
session the DSMB may review data by [CONTACT_110590] (pregnant women, infants) with all 
summaries for pregnant women and infants presented in aggregate over the treatment arms. In the closed session the DSMB may review unblinded data for the pregnant women and infant subject  groups. 
5.3.3. Reasons for Withdrawal and Discontinuation of Study Product Administration 
Subjects may voluntarily withdraw their consent for study participation at any time without penalty or loss of benefits to which they are otherwise entitled.  
An investigator may also withdraw a subject from receiving the study product for any reason. Follow-up safety evaluations will be conducted, if the subject agrees.  If a subject withdraws or 
is withdrawn prior to completion of the study, the reason for this decision must be recorded in 
the data collection  forms.  
The reasons, might include, but are not limited to the following: 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         48 
 • Subject no longer meets eligibility criteria  
• Subject meets individual halting criteria (reference to Sectio n 9.5) 
• Subject becomes noncompliant 
• Medical disease or condition, or new clinical finding(s) for which continued 
participation, in the opi[INVESTIGATOR_149048], interfere with the subject's successful completion of this study, or interfere with 
the evaluation of responses 
• Subject lost to follow -up 
• Determined by a physician’s discretion to require additional therapy not indicated in the 
protocol to ensure subject’s health and well- being (or treatment failure, if applicable)  
• New information becomes available that makes further participation unsafe or unwarranted. 
• Termination of this trial 
• Subject withdrawal of consent 
The i nvestigator should be explicit regarding study follow-up (e.g. safety follow- up) that might 
be carried out despi[INVESTIGATOR_122748].  If the subject consents, every attempt will be made to follow all AEs through resolution.  The procedures that 
collect safety data for the purposes of research must be inclusive in the original informed consent 
or the investigator may seek subsequent informed consent using an IRB/IEC-approved consent form with the revised procedures. The investigator will inform the subject that already collected data will be retained and analyzed 
even if the subject withdraws from this study.  
5.3.4. Handling of Withdrawals  and Discontinuation of Administration  
The primary reason for withdrawal from this trial will be recorded on the Study Status data 
collection form. Subject s will be encouraged to complete the Early Termination Visit. The Early 
Termination Visit procedures are listed in Section 7.6. 
Every attempt will be made to follow all adverse events, including solicited injection site and systemic reactions, unsolicited non-serious adverse events, serious adverse events, and pregnancy outcomes, ongoing at the time of early withdrawal, through resolution as per 
applicable collection times defined for the specific type of adverse event.  
In the case of subject s who fail to appear for a safety follow-up assessment, extensive effort (i.e., 
three documented contact [CONTACT_92238], e-mails, home visits, etc., made on separate occasions) will be made to locate or recall them, or at least to determine their  health status. These 
efforts will be documented in the subject’s records.  
DMID Protocol 16- [ADDRESS_576745] 
to follow-up, will not be replaced. The proposed sample size for the trial accounts for a 15% rate of subject loss.  
5.3.6. Termination of Study  
Although the sponsor has every intention of completing this trial, it reserves the right to 
terminate this trial at any time for clinical or administrative reasons. Reasons for termination include, but are not limited to, study closure due to DSMB review and recommendation and at the discretion of DMID. 
If the study is prematurely terminated by [CONTACT_456], any regulatory authority, or the 
investigator for any reason, the investigator will promptly inform the study subjects and assure appropriate therapy or follow -up for the subjects, as necessary. The investigator will provide a 
detailed written explanation  of the termination to the IRB/IEC.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         50 
 6. STUDY INTERVENTION/I NVESTIGATIONAL 
PRODUCT  
6.1. Study Product Description  
BOOSTRIX  
BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, 
Adsorbed) is a noninfectious, sterile, vaccine for intramuscular administration. It contains tetanus toxoid, diphtheria toxoid, and pertussis antigens (inactivated PT, formaldehyde -treated FHA , and 
PRN ). The antigens are the same as those in INFANRIX, but BOOSTRIX is formulated with 
reduced quantities of these antigens. Tetanus toxin is produced by [CONTACT_452408] a modified Latham medium derived 
from bovine casein. The diphtheria toxin is produced by [CONTACT_452409] a bovine extract. The bovine mater ials used in these extracts are 
sourced from countries which the [LOCATION_002] Department of Agriculture (USDA) has determined neither have nor are at risk of bovine spongiform encephalopathy (BSE). Both toxins 
are detoxified with formaldehyde, concentrated by [CONTACT_452410], and purified by [CONTACT_6440][INVESTIGATOR_332], 
dialysis, and sterile filtration.  
The acellular pertussis antigens (PT, FHA, and PRN ) are isolated from Bordetella pertussis 
culture grown in modified Stainer-Scholte liquid medium. PT and FHA are isolated from the fermentation broth; PRN  is extracted from the cells by [CONTACT_452411]. The 
antigens are purified in successive chromatographic and precipi[INVESTIGATOR_452343]. PT is detoxified using glutaraldehyde and formaldehyde. FHA and PRN  are treated with formaldehyde.  
Tetanus and diphtheria toxoid potency is determined by [CONTACT_452412][INVESTIGATOR_14107]. The potency of the acellular pertussis components (inactivated PT, formaldehyde- treated FHA , and PRN ) is determined by [CONTACT_452413]. BOOSTRIX is manufactured by [CONTACT_452414] 10 years and old and by [CONTACT_452415] 4 years and older. In Mali, the vaccine is not approved by [CONTACT_452416]. 
Tetanus and Diphtheria Toxoids Adsorbed (Td) Control Vaccine  
The Td control vaccine is prequalified by [CONTACT_141715] w ill be provided by [CONTACT_452417], as per standard of care.  It is indicated for  the active immunization of adults and children 
[ADDRESS_576746] diphtheria and tetanus.  Vaccine manufacturer details will be provided in the protocol- specific Manual of Procedures (MOP).  
6.1.1. Acquisition  
BOOSTRIX will be provided by [CONTACT_159270]. Upon request by [CONTACT_122830], BOOSTRIX will be 
shipped to the following address: 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         51 
 DMID Clinical Materials Services  (CMS ) 
Fisher BioServices  
[ADDRESS_576747] 
Germantown, MD [ZIP_CODE] 
Phone: [PHONE_6136] 
Fax: [PHONE_6137] 
Email: [EMAIL_1395] 
Study  vaccine (BOOSTRIX) will be provided through the DMID CMS to the each VTEU 
participating subcontracted VTEU site prior to the start of this trial upon request and with prior 
approval from DMID. Should the site principal investigator [INVESTIGATOR_452344], further instructions on requesting study vaccine will be provided in the protocol-specific MOP.  
Td control vaccine will be provided by [CONTACT_452418] (EPI) as per standard recommendations for vaccination of pregnant women. 
6.1.2. Formulation, Packaging, and Labeling 
BOOSTRIX  
Formulation 
Each 0.5-mL dose of vaccine is formulated to contain 5 Lf of tetanus toxoid, 2.5 Lf of diphtheria 
toxoid, 8 mcg of inactivated PT, 8 mcg of FHA, and 2.5 mcg of PRN  (69 kiloDalton outer 
membrane protein). Each 0.5-mL dose contains aluminum hydroxide as adjuvant (not more than 
0.39 mg aluminum by [CONTACT_135942]), 4.4 mg of sodium chloride, ≤100 mcg of residual formaldehyde, and ≤100 mcg of polysorbate 80 (Tween 80).   
Storage 
The vaccine must be stored at 2°C to 8°C (35°F to 46°F). Do not freeze. 
Packaging and Labeling 
The vaccine is supplied as 0.5 mL single-dose prefilled syringes. The tip caps of the prefilled 
syringes contain natural rubber latex; the plungers are not made with natural rubber latex.  
The study product will be labeled according to manufacturer specifications and include the statement “Caution: New Drug – Limited by [CONTACT_12201].”  
Td Control Vaccine 
Formulation The vaccine contains purified tetanus and diphtheria toxoids, with a reduced dose of the diphtheria component. One dose of 0.[ADDRESS_576748] 1.5  mg 
aluminum phosphate. Thimerosal 0.1 mg/ml is used as a preservative.  
  
DMID Protocol 16- [ADDRESS_576749] be stored at 2°C to 8°C (36°F to 46°F). Do not freeze.  
Packaging  The vaccine is supplied as 10-dose vials of [ADDRESS_576750] been 
removed during an immunization session may be used in subsequent immunization sessions for 
up to a maximum of 4 weeks, provided that all of the following conditions are met: 
• The expi[INVESTIGATOR_452345]; 
• The vaccines are stored under appropriate cold chain conditions; 
• The vaccine vial septum has not been submerged in water; 
• Aseptic technique has been used to withdraw all doses; 
• The vaccine vial monitor, if attached, has not reached the discard point. 
6.1.3. Product Storage and Stability  
The temperature of the storage unit will be recorded manually daily (excluding non-business 
days and holidays as applicable), continuously monitored during the duration of this trial per 
each participating VTEU site ’s standard operating procedures, and documentation will be 
maintained. If the temperature fluctuates outside of the required range, the affected study product(s) will be quarantined at the correct storage temperature and labeled as ‘Do Not Use’ 
until furt her notice. The research pharmacist or other study staff member designated to oversee 
the storage of the study product, will alert the site principal investigator [INVESTIGATOR_452346]. In the eve nt the temperature fluctuates 
outside of the required range, including accidental freezing or disruption of the cold chain, the affected study product(s) will not be administered without review and specific instructions from DMID. The site principal investigator [INVESTIGATOR_452347] 
[EMAIL_5255] for further instructions before any additional study 
vaccinations are administered. Based on the information collected, DMID and/or the manufacturer will determine whether the affected study product(s) can be used. If it cannot be 
used, the site will rece ive specific instructions on how to return the affected study product(s) to 
the DMID CMS or destroy it on site. Additional instructions for quarantine will be provided in 
the protocol- specific MOP.  
6.2. Dosage, Preparation and Administration of Study 
Interventi on/Investigational Product  
See the Prescribing Information and protocol-specific MOP for detailed information on the 
preparation, labeling, storage, and administration of study vaccine for each treatment arm. Study 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         53 
 vaccine preparation will be performed by [CONTACT_202407]’s  (or subcontracted site’s) 
research pharmacist or designee on the same day of study vaccine administration. 
Visually inspect the study vaccines upon receipt and prior to use. If the study product(s) 
appear(s) to have been damag ed, contaminated or discolored, contain visible particulate matter, 
or if there are any concerns regarding its integrity, do NOT use the affected study product(s). The 
affected study product(s) must be quarantined at 2°C to 8°C (35.6°F to 46.4°F) and label ed as 
‘Do Not Use’ (until further notice). The site principal investigator [INVESTIGATOR_294976] [EMAIL_5255] and DMID Clinical Project Manager for further instructions before any additional study vaccinations are administered. Based on the information 
collected, DMID and/or the manufacturer will determine whether the affected study product(s) 
can be used. If it cannot be used, the site will receive specific instructions on how to return the affected study product(s) to the DMID CMS or destroy it on site. If the study vaccines are 
unusable, study personnel will use another from the study supply. Replacement study vaccine 
(BOOSTRIX only) may be requested by [CONTACT_295023]. Additional instructions for 
quarantine and DMID contact [CONTACT_295025]- specific MOP.  
6.2.1. BOOSTRIX  
Dosage 
BOOSTRIX will be administered intramuscularly as a single 0.[ADDRESS_576751](s) appear(s) to have been damaged, contaminated or discolored, contain visible particulate matter, 
or if there are any concerns regarding its integrity, do NOT use th e affected study product(s). The 
affected study product(s) must be quarantined at 2°C to 8°C (35.6°F to 46.4°F) and labeled as 
‘Do Not Use’ (until further notice). The site principal investigator [INVESTIGATOR_452348] 
[EMAIL_5255] and DMID Clinical Project Manager for further 
instructions before any additional study vaccinations are administered.  
No study vaccine preparation is required for the BOOSTRIX vaccine as it is cont ained in a 
prefilled syringe and the entire contents will be administered to subjects’ pretreatment assignment. Prior to administration, shake vigorously to obtain a homogeneous, turbid, white suspension. Ensure that the plunger rod is firmly attached to the rubber stopper by [CONTACT_452419]. Do not over tighten. Remove syringe LUER Tip-
cap and needle cap. Attach needle by [CONTACT_452420] a clockwise rotation until secured 
to the syringe.  
6.2.2. Td Control Vac cine 
Dosage 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         54 
 Td control vaccine will be administered intramuscularly as a single 0.5 mL dose. 
Preparation The Td control vaccine vial should be shaken before use to homogenize the suspension. The Td 
control vaccine will be prepared by [CONTACT_452421] a 0.5 mL dose. Further details on the handling of the multi- dose vials will be 
described in the protocol- specific MOP.  
6.2.3. Administration  
Study vaccine will be administered as a single 0.5 mL intramuscular (IM) injection into the 
deltoid muscle of the subject’s preferred arm. The vaccine must NOT be administered intravenously, subcutaneously, or intradermally. The protocol-specific MOP contains additional information on how to administer IM injections. 
Each dose o f study vaccine will be administered as soon as possible, but no longer than [ADDRESS_576752] remain at room temperature until 
administered.  
6.3. 
Modification of Study Intervention/Investigational Product for a 
Subject  
There will be no dose modifications. All subjects will receive a single 0.5 mL dose of 
BOOSTRIX or Td control vaccine. For pregnant women, the dose will be administered between 14 0/7 weeks gestation and 26 6/7 weeks gestation. 
6.4. Accountability Procedures for the Study Intervention/Investigational 
Product(s)  
After receipt of the study vaccine, the site principal investigator [INVESTIGATOR_452349]. The site 
principal investigator [INVESTIGATOR_452350]’s (or subcontracted site’s) research pharmacist or designee. Each participating VTEU 
site’s research pharmacist or other qualified delegated research staff member will be responsible for maintaining complete records and documentation of study vaccine receipt, accountability, 
dispensing, temperature and storage conditions, and final disposition of the study vaccine. All 
study vaccine, whether administered or not, will be documented on the appropriate study product accountability record or dispensing log. The sponsor's monitoring staff will verify each participating VTEU site’s study product accountability records and dispensing logs per the site 
monitoring plan. 
Used and unused study vaccine will be retained until monitored and released for disposition as applicable. This may occur on an ongoing basis for used study vaccine. Final disposition of the 
unused study vaccine will be determined by [CONTACT_452422].  
DMID Protocol 16- [ADDRESS_576753] Compliance with Study 
Intervention/Investigational Product/Investigational Device   
Subject compliance is not anticipated to be an issue. The study vaccine is given as one dose at a 
single visit according to treatment assignment, administered by [CONTACT_452423].  Administration will be documented on the appropriate data 
collection form and entered into the electronic Case Report For m (eCRF ). 
6.6. Concomitant Medications/Treatments  
Subject  receipt of any medications, therapi[INVESTIGATOR_014], or vaccines will be recorded on the appropriate 
data collection form. Concomitant medications will include all current medications and 
medications taken within the 90 days prior to signing the informed consent form until discharge 
after delivery for pregnant women. For infants, concomitant medications will be recorded from 
birth until the day of life 180 visit. 
Medications/vaccinations reported in the eCRF are limite d to those taken within [ADDRESS_576754]  Exclusion Criteria (see Section 5.2). In addition, the site principal investigator [INVESTIGATOR_119251]-investigator may identify other medications that should not be used due to a risk to subject  
safety or assessment of reactogenicity and immunogenicity.  
DMID Protocol 16- [ADDRESS_576755] be in good health and meet all eligibility criteria. They will be enrolled at a 
referral health center of Commune I with prenatal and labor/delivery capabilities in Bamako, 
Mali . The target population will reflect the community at large. Estimated time to complete 
enrollment in this study is approximately [ADDRESS_576756]  Inclusion/Exclusion Criteria in DMID -sponsored studies. 
Questions about eligibility should be directed toward the DMID Medical Officer. 
7.2. Screening  
Screening Visit, Day -30 to Day 1: Clinic Visit, Pregnant Women (Visit 00 or V00) 
Potential subject s will be screened for eligibility within 30 days prior to the administration of the  
study vaccination. The following activities will be performed:  
• If not performed at the time of recruitment, s ubjects will be provided with a description 
of the study (purpose and study procedures) and asked to read and sign the informed consent form. The informed consent form will be signed prior to performing any study procedures, including any screening procedures. 
• Eligibility criteria will be reviewed with prospective subject s. 
• Complete medical history, including vaccination h istory, will be obtained by [CONTACT_452424].  
• All concomitant medications and vaccinations, as determined by [CONTACT_452425], taken within [ADDRESS_576757] s. Medications/vaccinations reported in the eCRF are limited to 
those taken within 30 days prior to study vaccination. 
• Obtain vital signs (oral temperature, pulse, blood pressure), height, and weight. Subjects 
will be asked not to eat or drink anything hot or cold, or smoke within 10 minutes prior to 
taking an oral temperature.  
• A targeted physical examination may be performed by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site principal investigator [INVESTIGATOR_119251]-investigator, if indicated based on review of complete medical history. For pregnant 
women, an examination performed by [CONTACT_452426] a targeted exam is called for.  
• An ultrasound will be performed to date the pregnancy. 
• Subject s will be given a research identification card that includes a photograph. 
7.3. Enrollment/Baseline  
Enrollment and Vaccination Visit, Day 1: Clinic Visit, Pregnant Women (Visit 01 or V01) 
• Reconfirm subject ’s willingness to participate prior to performing any study procedures, 
including administration of the study vaccination.  
• Obtain informed consent (if screening and enrollment visits have been combined).  
• Review eligibility criteria with subject s prior to the study vaccination to ensure 
eligibility.  
• Complete medical history and any updates obtained by [CONTACT_10393]/or review of medical charts of subject s since the screening visit will be reviewed with subject s prior to 
the study vaccination to ensure eligibility.  
• All concomitant medications and vaccinations will be reviewed with subject s prior to the 
study vaccination for accuracy and completeness. Any new concomitant medications/vaccinations taken since the screening visit will be reviewed with subject s 
and used in the assessment for eligibility, prior to the study vaccination. Medications reported in the eCRF are limited to those taken within 30 days prior to the study vaccination.  Subjects will be reminded they should not plan to receive any live or 
inactivated vaccine within 30 or 14 days, respectively, after study vaccination. 
• Vital signs, namely oral temperature, pulse, and blood pressure, will be obtained prior to the study vaccination. Vital signs assessed on Day [ADDRESS_576758] s will be asked not to eat or drink anything hot or cold, or 
smoke within 10 minutes prior to taking an oral temperature. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         58 
 • Height and weight will be obtained, if not done on screening visit. 
• A targeted physical examination may be performed prior to the study vaccination by a 
study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site principal investigator [INVESTIGATOR_11637]-investigator, if indicated based on review of 
complete medical history an d any updates obtained by [CONTACT_452427]. For pregnant women, an examination performed by 
[CONTACT_452426] a targeted exam is called for.  
• Approximately 30 mL of venous blood will be collected immediately prior to the study 
vaccination for baseline serology and cytokine assays. 
• Subjects will be enrolled in Advantage eClinical and assigned to treatment arm (BOOSTRIX or Td) and post-partum study schedule. 
• Pre-admi nistration solicited event assessments will be performed prior to study 
vaccination to establish baseline. Subjects will then receive a single dose of study vaccine 
via IM injection into the deltoid muscle of the subject  preferred arm. The site of injectio n 
(right or left arm) and time of administration will be recorded on the appropriate data collection form. Subject s will be observed in the clinic for at least [ADDRESS_576759]-admini stration 
solicited event assessments will be performed, and any AE/SAEs will be assessed and recorded on the appropriate data collection form prior to discharge from the clinic. 
• Subjects’ home addresses will be recorded so study personnel may complete follow-up home visits.  
• Subject s will be instructed to notify the study center if they develop any severe reactions 
after the study vaccination. If the site principal investigator [INVESTIGATOR_29353] -
investigator deems the reaction severe enough, s/he will give further instructions on the 
proper course of action, including a return to the clinic for immediate evaluation if appropriate. 
• It is possible the screening and enrollment visits may occur at the same time.  
7.4. Follow -up 
Follow-up visits are scheduled in reference to the study vaccination date (Day 1) as indicated for each visit window. The types of follow-up visits are described below as home visits, and clinic visits. See Appendix A  for specific study visits/days and study procedures and evaluations to be 
conducted at each follow -up visit. At any time during the follow -up period of pregnant women, 
study personnel may review her medical chart to gather information about the current pregnancy that is relevant to the conduct of this study.  If a woman experiences a stillbirth, all specimen 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         59 
 collection will stop, however the mother will be followed for safety until 6 months after the 
stillbirth.  
7.4.1. Clinic or Home Visits  
These visits will occur in person at the clinic or may  be conducted by [CONTACT_452428]’ homes. 
[IP_ADDRESS]. Post Study Vaccination Follow-up Visit, Day 4 (± 1 d): Home Visit, Pregnant 
Women (Vis it 02 or V02) 
• This visit will take place in the clinic or alternatively by [CONTACT_452429] (FWs) . 
• Study personnel will obtain interim medical history , including an assessment for new 
medical conditions by [CONTACT_452430] s and note any changes since the previous visit. 
• Study personnel will review solicited AEs with subject s and assess and record a ll 
solicited data, AE/SAEs, unsolicited AEs, and concomitant medications/vaccinations on 
the appropriate data collection forms. FWs will be trained on the assessment of local and 
systemic reactogenicity. If  the subject reports an AE  that is either  not included among the 
solicited AEs or is a grade [ADDRESS_576760] a  study clinician. The 
study clinician will either visit the participant at home or the participant will be referred 
to the study health center based on the FW’s a ssessment.  
[IP_ADDRESS]. Post Study Vaccination Follow-up Visit, Day 8 (+3 d): Home Visit, Pregnant 
Women (Visit 03 or V03) 
• This visit will take place in the clinic or alternatively by [CONTACT_452431] . 
• Study personnel will obtain interim medical history , including an assessment for new 
medical conditions, by [CONTACT_452432].  
• Study personnel will review solicited AEs with subject s and assess and record all 
solicited data, AE/SAEs, unsolicited AEs, and concomitant medication s/vaccinations  on 
the appropriate data collection forms. FWs will be trained on the assessment of local and systemic reactogenicity. If the subject reports an AE that is either not included among the 
solicited AEs or is a grade [ADDRESS_576761] a study clinician. The 
study clinician will either visit the participant at home or the participant will be referred to the study health center based on the FW’s assessment. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         60 
 7.4.2. Clinic Visits  
[IP_ADDRESS]. Immunology and Safety Follow-up Visit, [ADDRESS_576762] Study Vaccination Visit, 
Day 31 (±4 d): Clinic Visit, Pregnant Women (Vis it 04 or V04) 
• Study personnel will reconfirm subject ’s willingness to participate prior to performing 
any study procedures. They will also obtain an interim medical history, including an 
assessment for new medical conditions by [CONTACT_452433], home visit, or phone call. Study personnel will confirm 
that all eligibility criteria continue to be met.  
• Study personnel will review the solicited AEs with subjects, if not already reviewed and 
recorded during previous visits, and assess and record all new AE/unsolicited AEs/ SAEs 
and concomitant medications/vaccinations on the appropriate data collection forms. 
• Vital signs, namely oral temperature, pulse, and blood pressure will be obtained. Subject s 
will be asked not to eat or drink anything hot or cold, or smoke within 10 minutes prior to 
taking an oral temperature.  
• A targeted physical examination may be performed by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA [ADDRESS_576763]’s own obstetrical clinician may also provide data when a targeted 
exam is called for.  
• The study vaccination site will be examined.  
• Approximately [ADDRESS_576764]-vaccination serology and cytokine assays. 
[IP_ADDRESS]. Subsequent Follow -up Visits  
[IP_ADDRESS].1. Labor and Delivery Visit, Birth (+3 d): Clinic Visit, Pregnant Women and 
Infants (Visit 05 or V05) 
• Obtain interim medical history, including an assessment for  new medical conditions by 
[CONTACT_452430] s and note any changes since the previous clinic visit. Study 
personnel will solicit and record all new SAEs (as well as AEs  (solicited and unsolicited) ) 
and concomitant medications/vaccinations if less than [ADDRESS_576765] vaccination) on the 
appropriate data collection form. 
• Vital signs, namely oral temperature, pulse, and blood pressure, will be obtained. Subject s will be asked not to eat or drink anything hot or cold, or smoke within [ADDRESS_576766] may be used in lieu of study personnel performing vital sign 
measurements.  
• A targeted physical examination may be performed by a study clinician licensed to make 
medic al diagnoses and listed on the Form FDA [ADDRESS_576767] ’s own obstetrical clinician may also provide data when a 
targeted exam is called for.  
• On admission for parturition, 30 mL of blood will be drawn from the pregnant woman for 
serology. When possible, this blood will be drawn at the time of admission labs.  
• After delivery , study personnel will review the study procedures required for the infant 
going forward, add the infant ’s name [CONTACT_452465], and ask the woman  to 
acknowledge her  infant’s participation as well as her continuing participation by [CONTACT_452434]. 
• If possible, 20- [ADDRESS_576768] blood is preferred over venipuncture. 
• Study personnel will record birth outcomes on the appropriate data collection form. 
• Colostrum or breast milk, 10-[ADDRESS_576769] 4 days of life of the 
infant.  
• The newborn infant will be enrolled into the study at the time of birth. A targeted 
physical examination may be performed by a stu dy clinician licensed to make medical 
diagnoses and listed on the Form FDA 1572 as the site principal investigator [INVESTIGATOR_11637]-investigator, if indicated based on review of interim medical history. A physical exam performed by [CONTACT_58076]’s doctor may also provide information, if required, for documentation. 
• Axillary temperature, heart rate, respi[INVESTIGATOR_697],  head circumference, length, and weight 
will be collected from the medical chart of the infant. If not performed as part of routine care, these measurements,  except  weight  may be taken by [CONTACT_452435] 7 days of life. Weights will only be recorded when obtained at birth. 
• For infants, study personnel will solicit and record on the appropriate data collection form infant AEs, SAEs, and concomitant medications/vaccinations until the day of life 180 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         62 
 visit. Only medically attended AEs will be recorded. Events associated with routine 
newborn care and health maintenance visits will not be recorded. 
• To collect cord blood and to perform  physical examination of the mother and newborn at 
delivery, an on-call team comprised of a study physician and nurse will be posted at the recruitment site close to the delivery room. This team will collaborate with the local on -
call team. The team will refer to the study ID or consent form to confirm the 
identification of the participant.  
[IP_ADDRESS].2. 6 Weeks Postpartum Safety Follow-up Visit, Birth + Day 42 (±5 d): Clinic Visit, 
Postpartum Women and Infants (Visit 06 or V06) 
• Obtain interim medical history of mother and  infant, including an assessment for new 
medical conditions by [CONTACT_452430] s and note any changes since the previous 
clinic visit. Study personnel will solicit and record all new congenital anomalies  and 
SAEs on the appropriate data collection form. 
• Study personnel will record infant concomitant medications on the appropriate data 
collection form.  
• A targeted physical examination may be performed by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site princ ipal investigator or 
sub-investigator, if indicated based on review of interim medical history. A targeted 
physical exam may be performed on the mother, infant, or both. 
• 5 mL of infant venous blood will be collected for serology and cytokine assessments. 
• 10-[ADDRESS_576770] milk will be collected from the mother for antibody measurements.  
• Study personnel will collect  infant length,  weight , and head circumference as well as 
birth outcomes on the appropriate data collection form. 
[IP_ADDRESS].3. 10 or 18 Weeks Postpartum Safety Follow-up Visit, Birth + Day 70 (±5 d) or 
Birth + Day 130 (±5 d): Clinic Visit, Postpartum Women and Infants (Visit 07 or V07) 
• Obtain interim medical history of mother and infant, including an assessment for new 
medical conditions by [CONTACT_452436] s and note any changes since the previous 
clinic visit. Study personnel will solicit and record all new congenital anomalies and 
SAEs on the appropriate data collection form. 
• Study personnel will record infant concomitant medications on the appropriate data 
collection form.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         63 
 • A targeted physical examination may be performed by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site principal investigator [INVESTIGATOR_11637]-investigator, if indicated based on review of interim medical history. A targeted 
physical exam may be performed on the mother, infant, or both. 
• 5 mL of infant venous blood will be collected for serology and cytokine assessments prior to receipt of DTwP.  
• 10-[ADDRESS_576771] milk will be collected from the mother for antibody measureme nts. 
• Study personnel will collect  infant length , weight , and head circumference as well as 
birth outcomes on the appropriate data collection form. 
7.5. Final Study Visit  
6 months Postpartum Safety Follow-up Visit, Birth + Day 180 (±7 d): Clinic Visit, Postpartu m Women and Infants (Visit 08 or V08) 
• Obtain interim medical history of mother and infant. Study personnel will solicit and record all new congenital anomalies and SAEs on the appropriate data collection form. 
• Study personnel will record infant concomitant medications on the appropriate data collection form.  
• A targeted physical examination may be performed by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site principal investigator [INVESTIGATOR_119251]-investigator, if indica ted based on review of interim medical history. A targeted 
physical exam may be performed on the mother, infant, or both. 
• 5 mL of infant venous blood will be collected for serology assessments. 
• Approximately [ADDRESS_576772]-
vaccination serology and cytokine assays. 
• 10-[ADDRESS_576773] milk will be collected from the mother for antibody measurements.  
• Study personnel will collect  infant length , weight , and head circumference as well as  
birth outcomes on the appropriate data collection form. 
• Study personnel will discharge mother and infant from study. 
7.6. Early Termination Visit  (if needed)  
The following activities will be performed at the early termination visit for subject s who 
withdraw, or are withdrawn or terminated from this study:  
• Obtain interim medical history, including an assessment for new medical conditions by 
[CONTACT_452437], if applicable, and note any changes 
since the previous clinic visit or phone call. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         64 
 • Obtain vital signs: heart rate, blood pressure, and temperature. Subjects will be asked not 
to eat or drink anything hot or cold, or smoke within 10 minutes prior to taking an oral temperature.  
• Study personnel will collect  infant length, weight , and head circumference as well as 
birth outcomes on the appropriate data collection form. 
• Review solicited AEs (if within 8 days after the study vaccination or if after the 8- day 
period but the AE information had not previously been collected). 
• All concomitant medications/vaccinations will be recorded on the appropriate data collection form (if within the period of collection of concomitant medications).  
• Review adverse events (if within the collection period for AEs). 
• Review serious adverse events, if within the collection period for SAEs. 
• A targeted physical examination may be performed  on the mother and/or infant by a 
study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site principal investigator [INVESTIGATOR_11637]- investigat or, if indicated based on review of interim 
medical history.  
• Examine study vaccination site (if within 30 days after the study vaccination).  
• Record birth outcomes, if applicable. 
7.7. Unscheduled Visit (if needed)  
Unscheduled visits may occur at any time during this study. Any of the following activities may 
be performed:  
• Obtain interim medical history, including an assessment for new medical conditions by 
[CONTACT_452437], if applicable, and note any changes 
since the previous clinic visit or phone call.  
• Obtain vital signs: heart rate, blood pressure, and temperature. Subjects will be asked not to eat or drink anything hot or cold, or smoke within 10 minutes prior to taking an oral 
temperature.  
• Study personnel will collect  infant length, weight, and head circumference as well as 
birth outcomes on the appropriate data collection form. 
• Review solicited AEs (if within 8 days after the study vaccination or if after the 8- day 
period but the AEs had not previously been collected). 
• Review concomitant medications/vaccinations (if within the collection period for 
concomitant medications).  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         65 
 • Review adverse events (if within the collection period for AEs). 
• Review serious adverse events, if within the collection period for SAEs.  
• A targeted physical examination may be performed on the mother and/or infant by a 
study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site principal investigator [INVESTIGATOR_11637]-investigator, if indicated based on review of interim medi cal history.  
• Examine study vaccination site (if within 30 days after the study vaccination).  
• Record birth outcomes, if relevant. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
         66 
 8. STUDY PROCEDURES/EVALUATIONS  
8.1. Clinical Evaluations  
Complete medical history to determine eligibility will be obtained by [CONTACT_452438]. The information will be obtained at the 
screening visit and will be updated on Day 1, prior to study vaccination. Subject s and records, 
when available, will be queried regarding a history of significant medical disorders of the head, eyes, ears, nose, throat, mouth, cardiovascular system, lungs, gastrointestinal tract, liver, 
pancreas, kidney, urologic system, nervous system, blood, lymph nodes, endocrine system, 
musculoskeletal system, skin, and genital/reproductive tract. A history of any allergies, cancer, immunodeficiency, psychiatric illness, substance abuse, and autoimmune disease will be 
solicited. At follow -up visits, an interim medical history will be obtained by [CONTACT_452439] s and review of the medical chart of pregnant women when needed, noting any changes 
since the previous clinic visit or phone call. The interim medical history will include an 
assessment for new medical conditions and symptoms. 
Medications history (con comitant medications) will include a review of all current medications 
through the intervals described in Section 6.6 (Concomitant Medications/Treatments). 
Prescri ption and over-the-counter drugs will be included as well as vaccines, herbals, vitamins, 
and supplements. Use of any new medication should prompt evaluation for the presence of a new 
diagnosis, unless the medication is an expected medication in the care o f a pregnant woman. 
Examples of medications used in the care of pregnant women that would not prompt evaluation for a new diagnosis would be prenatal vitamins for all women and RhoGAM for Rh(D)- negative 
women. Assessment of eligibility will include a revie w of all permitted and prohibited 
medications per the Subject  Inclusion and Exclusion Criteria. In addition, the site principal 
investigator [INVESTIGATOR_29353]-investigator may identify other medications that should not be used due to a risk to subject  safety or assessment of reactogenicity and immunogenicity.  
At the screening visit, a targeted physical examination, if indicated based on subject’s complete medical history, may be performed by a study clinician licensed to make medical diagnoses and listed o n the Form FDA [ADDRESS_576774] ’s clinician may also be 
used. On Day 1, prior to the vaccination, and as needed at follow-up visits af ter vaccination, a 
targeted physical examination may be performed by a study clinician licensed to make medical diagnoses and listed on the Form FDA [ADDRESS_576775] ’s interim me dical history. Targeted physical examinations are 
performed to investigate further symptoms reported by [CONTACT_452440].  
Vital signs (oral temperature, pulse, and blood pressure) will be collected on Day [ADDRESS_576776] s 
will be asked to not eat or drink anything hot or cold, or smoke within the 10 minutes prior to 
taking an oral temperature.  
Solicited event assessments will include an assessment of solicited adverse events occurring from the time of vaccination (Day 1) through Day 8. These assessments include injection site (local) reactions of ecchymosis (bruising), erythema (redness), induration (hardness)/edema 
(swelling), pain, and tenderness as well as systemic reactions including fever, feverishness (chills/shivering/sweating), fatigue (tiredness), malaise (general unwell feeling), myalgia (body aches/muscular pain exclusive of the injection site), arthralgia (joint pain exclusive of the injection site), headache, nausea, and allergic reaction (pruritus/urticaria). Pre- administration 
solicited systemic event assessments will be performed prior to study vaccination to establish 
baseline, then the study vaccination will be given. Subject s will be observed in the clinic for at least [ADDRESS_576777]- administration solicited event assessments will be 
performed, and any AE/SAEs will be assessed and recorded on the appropriate data collection form prior to discharge from the clinic. A field worker will visit all subject s on Days [ADDRESS_576778] information on so licited adverse events and any AE/SAEs. The study vaccination site will 
also be examined on Day 31. 
8.2. Laboratory Evaluations  
8.2.1. Clinical Laboratory Evaluations 
Clinical screening laboratory parameters are not included in the routine evaluation for eligibility. If the medical record or history reveals laboratory abnormalities that might preclude eligibility or 
affect subject  safety or the investigator’s ability to  assess the safety, tolerability, or 
immunogenicity of the vaccine, the investigator may use that information to determine 
eligibility.  
  
DMID Protocol 16- [ADDRESS_576779] Milk and Colostrum:   The exploratory measurement of antibody to Tdap antigens in 
colostrum/breast milk will be performed at VTEU site laboratories using qualified ELISAs. 
These ass ays have not been validated for colostrum/ breast milk. 
Laboratory personnel performing all assays will be blinded as to the allocation arm of pregnant 
subject s (Tdap vs. Td), study visit number, and whether the samples are from adult or infant 
subject s. The volume of venous blood and colostrum/breast milk to be collected for assays is 
presented in Table 2. 
 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          70 
 8.2.3. Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007]  
[IP_ADDRESS]. Instructions for Specimen Preparation, Handling, and Storage  
Instructions for specimen preparation, handling, and storage are included in the protocol- specific 
MOP, as appropriate. 
[IP_ADDRESS]. Specimen Shipment  
Specimen shipment will occur at intervals during the course of this trial following all applicable 
International Air Transport Association (IATA) requirements and according to the specifics for 
storage temperature and documentation as detailed in the protocol-specific MOP, as appropriate. Further instructions for specimen shipment will be included in the protocol- specific MOP, as 
appropriate. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          71 
 9. ASSESSMENT OF SAFETY  
9.1. Specification of Safety Paramet ers 
Safety will be assessed by [CONTACT_452441]: 
1) Study vaccine- related Serious Adverse Events occurring from the time of the study 
vaccination through the visit 6 months postpartum ( 180 days of life for the infant visit) 
for preg nant subject s and infants. All SAEs during this timeframe will be assessed and 
documented. 
2) Adverse Events related to pregnancy and the infant as delineated below in Section 9.2.4. 
For the pregnant woman/mother: pregnancy loss, vaginal bleeding (antepartum or 
postpartum), post- abortal endometritis/salpi[INVESTIGATOR_8937], preterm rupture of membranes, 
preterm contractions/labor/delivery, poor fetal growth, hypertension/pre-eclamp sia/eclampsia, chorioamnionitis, postpartum endometritis, gestational diabetes 
mellitus. For the infant: preterm birth, low birth weight, neonatal complications, and congenital anomalies.  
3) Solicited Adverse Events – reactogenicity events occurring from the time of study 
vaccination through 7 days after study vaccination (Day 8) or until resolution. 
a. Injection site reactions including ecchymosis (bruising), erythema (redness), 
induration (hardness)/edema(swelling), pain, and tenderness. 
b. Systemic reactions including fever (days 4 and 8 only during home visits), 
feverishness (chills/shivering/sweating), fatigue (tiredness), malaise (general unwell feeling), myalgia (body aches/muscular pain exclusive of the injection 
site), arthralgia (joint pain exclusive of the  injection site), headache, nausea, and 
allergic reaction (pruritus/urticaria).  
4) Unsolicited  Non -Serious Adverse Events – all non-serious unsolicited adverse events will 
be assessed and documented, and all study vaccine -related non -serious adverse events  
occurring from the time of study vaccination through approximately 30 days after study 
vaccination (the Day 31 visit). For pregnant women who deliver before Day 31, unsolicited adverse events will be recorded until delivery. 
5) Major Congenital Anomalies Congenital Anomalies: In this study, we will report as SAEs all major congenital anomalies known prior to a mother/infant dyad completing the study. These outcomes must occur following maternal vaccination during gestation or the perinatal period 
(within the first 5 days after delivery) but the diagnosis may be confirmed anytime during 
participation. We define “major congenital anomaly” as “defects that are present at birth and that have surgical, medical, or serious cosmetic significance.” [33] 
The following list of problems are among the conditions reported in the US National 
Birth Defects registry and would be deemed as examples of major congenital anomalies: 
DMID Protocol 16- [ADDRESS_576780]-axial polydactyly, ankyloglossia, and epi[INVESTIGATOR_452351]. 
Positional deformations, such as molding or overriding cranial sutures, metatarsus 
adductus, tibial torsion, and genu varum are not t o be recorded as major congenital 
anomalies. Normal variants, such as minor anomalies of the pi[INVESTIGATOR_24277], supernumerary 
nipples, and penile torsion are also not major congenital anomalies. If major congenital 
anomalies are found prenatally, before enrollment, wo men will be excluded from 
participation. Many minor congenital anomalies will typi[INVESTIGATOR_452352].  
9.2. Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  
9.2.1. Adverse Events  
Adverse Event:  
ICH E6 defines an AE as  any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product regardless of its causal relationship to the study 
treatment. FDA defines an AE as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of medicinal (investigational) 
product. The occurrence of an AE may come to the attention of study personnel during study visits and interviews of a study recipi[INVESTIGATOR_12189], or upon review by a study 
monitor. 
AEs, including solicited local (injection site) and systemic (subjective and quantitative) 
reactions , will be captured on the appropriate data collection form and eCRF.  Information to be 
collected for unsolicited non- serious AEs includes event description, date of onset, assessment of 
severity , relationship to study product and alternate etiology  (assessed only by [CONTACT_21218] a diagnosis and listed on the Form FDA 1572 as an investigator), 
date of resolution, seriousness and outcome. FWs will be trained on the as sessment of local and 
systemic reactogenicity. If the subject reports an AE that is either not included among the 
solicited AEs or is a grade [ADDRESS_576781] a study clinician . The study 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          73 
 clinician will either visit the participant at home or the participant will be referred to the study 
health center based on the FW’s assessment. AEs occurring during the trial collection and 
reporting period will be documented appropriately regardless of relationship. AEs will be 
followed through re solution. 
Any medical condition that is present at the time that the subjec t is screened will be considered 
as baseline and not reported as an AE. However, if the severity of any pre- existing medical 
condition increases, it should be recorded as an AE. 
All AEs must be graded for severity and relationship to study product (see definitions) . Adverse 
events characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865]. 
The start and stop date of each reported AE will be recorded on the appropriate data collection 
form and eCRF. 
Severity of Event:  AEs will be assessed by [CONTACT_55296] a protocol- defined grading 
system  (toxicity table included as an appendix). For events not included in the protocol- defined 
grading system, the following guidelines will be used to quantify severity: 
• Mild (Grade 1) :  Events require minimal or no treatment and do not interfere with the 
subject’s daily activities.  
• Moderate (Grade 2) :  Events result in a low level of inconvenience or concern with 
therapeutic measures.  Moderate events may cause some interference with functioning 
and daily activities.  
• Severe (Grade 3) :  Events interrupt the subject’s daily activities and may require systemic 
drug therapy or other treatment.  Severe events are usually incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
Relationship to Study Products: The assessment of the relationship of an AE to the 
administration of study product is made only by [CONTACT_8703] a diagnosis and listed on the Form FDA [ADDRESS_576782]. To help assess, the following 
guidelines are used. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          74 
 • Related  – There is a reasonable possibility that the study product caused the adverse 
event. Reasonable possibilit y means that there is evidence to suggest a causal relationship 
between the study product and the adverse event. 
• Not Related  – There is not a reasonable possibility that the administration of the study 
product caused the event. 
9.2.2. Reactogenicity (for Vaccine Studies and Some Therapeutic Trials)  
Reactogenicity events are AEs that are common and known to occur following administration of 
this type of study vaccine. The following Toxicity Grading Scales will be used to grade solicited 
local (injection site) and systemic (subjective and quantitative) reactions: 
Table 3: Local (Injection Site) Reactogenicity Grading  
Local (Injection Site) 
Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Pain  Does not interfere with 
daily activity  Repeated use of non -
narcotic pain reliever > 24 
hours or interferes with 
daily activity  Any use of narcotic pain 
reliever or prevents daily 
activity  
Tenderness  Discomfort only to deep 
palpation  Discomfort to light 
palpation or movement  Significant discomfort to 
any touch or movement  
Ecchymosis (Bruising)*  No interference with daily 
activity  Some interference with 
daily activity not requiring 
medical intervention  Prevents daily activity and 
requires medical 
intervention  
Erythema (Redness)*    Does not interfere with 
daily activity    Interferes with daily 
activity  Prevents daily activity  
Induration 
(Hardness)/ Edema 
(Swelling )*   Does not interfere with 
daily activity    Interferes with daily 
activity  Prevents daily activity  
 
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          75 
 Ecchymosis (bruising), erythema (redness), and induration (hardness)/ edema ( swelling ) as 
analyzed by [CONTACT_319679]:  
 
Table 4: Local (Injection Site) Reactogenicity Measurements  
Local (Injection Site) Reaction  Small  Medium  Large  
Ecchymosis (Bruising)*  1-50 mm  51-100 mm  > 100 mm  
Erythema (Redness)*  1-50 mm  51-100 mm  > 100 mm  
Induration (Hardness)/ Edema 
(Swelling )* 1-50 mm  51-100 mm  > 100 mm  
  *Will not be used as halting criteria.  
 
In addition to grading the measured local reactions at the greatest single diameter, the 
measurements will be recorded as continuous variables. 
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          76 
 Table 5: Subjective  Systemic Reactogenicity Grading  
Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Feverishness 
(Chills/Shivering/Sweating)  No interference 
with daily activity  Some interference with 
daily activity not 
requiring medical 
intervention  Prevents daily activity and 
requires medical 
intervention  
Fatigue (Tiredness)  No interference 
with daily activity  Some interference with 
daily activity  Significant; prevents daily 
activity  
Malaise (General Unwell 
Feeling)  No interference 
with daily activity  Some interference with 
daily activity not 
requiring medical 
intervention  Preve nts daily activity and 
requires medical 
intervention  
Myalgia (Body 
Aches/Muscular Pain)*  No interference 
with daily activity  Some interference with 
daily activity  Significant; prevents daily 
activity  
Arthralgia (Joint Pain)*  No interference 
with daily activity  Some interference with 
daily activity not 
requiring medical 
intervention  Prevents daily activity and 
requires medical 
intervention  
Headache No interference 
with daily activity  Repeated use of non -
narcotic pain reliever > 
24 hours or some 
interfer ence with daily 
activity  Significant; any use of 
narcotic pain reliever or 
prevents daily activity  
Nausea  No interference 
with daily activity  Some interference with 
daily activity  Prevents daily activities  
Allergic Reaction  Pruritus without 
rash  Localized urticaria OR 
requires oral therapy  Generalized urticaria; 
angioedema OR 
anaphylaxis OR requires 
epi[INVESTIGATOR_238]  
  *Not at injection site.  
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          77 
 Oral temperature# will be graded as follows: 
 
Table 6: Quantitative  Systemic Reactogenicity Grading  
Systemic (Quantitative)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever* - oral† 38.0 – 38.4°C  
100.4 – 101.1°F  38.5 – 38.9°C  
101.2 – 102.0°F  > 38.9°C  
> 102.1°F  
#Oral temperature assessed on Day 1 prior to study vaccination will be considered as baseline.  
*A fever can be considered not related to the study product if an alternative etiology can be documented.  
†Subject s must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
9.2.3. Additional Adverse Event Severity Grading  
Pulse and blood pressure# will be graded as follows: 
Table 7: Pulse and Blood Pressure Severity Grading  
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia - beats per minute 50 – 54 or 45 -50 if 
baseline <60 bpm  45 – 49 or 40 -44 if 
baseline <60 bpm  < 45 or <40 if baseline 
<60 bpm  
Tachycardia - beats per minute 101 – 115 116 – 130 > 130 or ventricular 
dysrhythmias  
Hypotension (systolic) mm Hg  85-89 80-84 < 80 
Hypertension (systolic) mm Hg  141-150 151-160 > 160  
Hypertension (diastolic) mm Hg  91-95 96-109 > 109  
#Pulse and blood pressure assessed on Day 1 prior to the study vaccination will be considered as baseline.  
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          78 
 9.2.4. Grading of Specific Adverse Events in the Pregnant Women and their Infants  
Table 8: Maternal and Infant Adverse Events  
Maternal Adverse Events  
(Adverse Events during Pregnancy ) 
Parameter  Normal  Grade 1  Grade 2  Grade 3   
Pregnancy loss (Pregnancy 
does not result in a live 
birth)  
Spontaneous abortion or 
miscarriage in the first or 
second trimester of 
gestation  
   
 
Fetal death at or after 20 
weeks of gestation 
(stillbirth)  None  N/A N/A Spontaneous 
abortion or 
miscarriage   
Bleeding (vaginal) during 
pregnancy  prior to the 
onset of labor  None  Spotting or 
bleeding less than menses  Bleeding like 
menses or heavier, no intervention 
indicated  Profuse bleeding 
with dizziness or 
orthostatic 
hypotension, 
transfusion 
indicated   
Postpartum hemorrhage  
 EBLc ≤500 cc for 
vaginal delivery or  
≤1000 cc after CS or reported as 
normal  
 EBL 501 -1000 for 
vaginal delivery or 1001- 1500 for CS 
or reported as 
slightly increased  
 EBL >1000 for 
vaginal delivery or  
>1500 for CS, with or without mild dizziness, no 
transf usion required  
 Hemorrhage at a 
level for which transfusion of 
packed cells or any amount of 
other blood 
components is 
indicated   
Postabortal 
endometritis/salpi[INVESTIGATOR_452353], 
resolved with oral 
antibiotics  
 Moderate 
symptoms, requiring ≤3 days 
of parenteral 
antibiotics  
 Severe symptoms 
requiring >3 days of IV antibiotics 
or development 
of TOA   
Preterm rupture of 
membranes  
 None  N/A Preterm rupture but 
not resulting in delivery before 37 
weeks gestation  Preterm rupture 
resulting in 
delivery before  
37 weeks 
gestation   
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          79 
 Preterm contractions 
/labor/deliverye 
 
 None  
Braxton Hicks 
contractions  
(as early as second trimester)  Preterm 
contractions which resolve without 
medical 
intervention  
 Preterm 
contractions with cervical change 
which result in 
medical 
intervention but not 
resulting in preterm 
delivery  Delivery before 
37 weeks gestation   
Poor fetal growth  
If infant is small for gestational age on newborn 
exam: report as 
NEONATAL OUTCOME  
based on birth weight  
(see below)  At or above 10th 
percentile  
 Fetal growth <10th 
percentile but ≥3rd 
percentile for 
gestational age by 
[CONTACT_2207]   
 N/A Fetal growth <3rd 
percentile for gestational age by 
[CONTACT_452442], 
preeclampsia/eclampsia  None  Pregnancy induced 
hypertension  Preeclampsia  HELLP 
syndrome, or eclampsia,   
Chorioamnionitis  
 None  Fever (38°C –
38.4°C or 
100.4°F –100.9°F) 
with two or more: FHR
e >160 BPMf, 
maternal HR >120, uterine 
tenderness between 
contractions or 
purulent AF or 
preterm labor  Same as Grade 1 
plus fever 38.5°C –
40°C or 101°F –
104°F  
 Criteria for Grade 
2 plus fetal distress or fever 
>40°C or 104°F   
Postpartum endometritis  
 None  Low grade fever 
and uterine tenderness, 
resolved with oral 
antibiotics  Moderate 
symptoms, treated by ≤3 days of 
parenteral 
antibiotics  
 Severe symptoms 
treated with >3 days of IV 
antibiotics, 
addition of 
heparin, or 
operative 
intervention   
Gestational d iabetes 
mellitus  N/A  New onset 
controlled by [CONTACT_452443][INVESTIGATOR_452354], pregnancy -
related, NOT identified 
elsewhere in this AE 
Grading Table  None  Symptoms causing 
no or minimal 
interference with usual social & functional activities  
 Symptoms causing 
greater than 
minimal 
interference with usual social & functional activities  
 Symptoms 
causing inability 
to perform usual 
social & functional activities  
 
  
 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          80 
 Mode of deliveryf 
(normal spontaneous vaginal 
delivery, induced delivery, 
assisted vaginal delivery, 
Caesarean Section)  Not reported as AE/SAE . Mode of delivery  is a procedure and should not be reported or 
graded as an AE/SAE. The reason for selecting the mode of delivery (for example: Caesarean Section for severe preeclampsia ) should be reported and graded as appropriate.    
  
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          81 
 Infant Adverse Events  
(Neonatal and Infant Events ) 
Parameter  Normal   Grade 1   Grade 2   Grade 3   
Preterm birthg 
 
 Born after 36 6/7 
weeks gestation  
 Late preterm:  
34 to 36 6/7 weeks gestation  
 Early preterm:  
32 to 33 6/7 weeks gestation  
 Very or 
extremely preterm:  
< 31 6/7 weeks 
gestation   
Birth weight (grams)g  
(Small, appropriate, large for gestational age)  
 
Report separately poor fetal  
growth  
(as above)  Birth weight 
>2500   Low birth weight: 
1501- 2500  Very low birth 
weight ≤1500   
Neonatal complications  
in a term infant Normal term 
infant discharged 
home with mother after uncomplicated 
delivery and 
nursery course  
 Transient signs 
and symptoms requiring  no 
intervention, and resolved 
spontaneously
h Signs/symptoms 
requiring 
interventioni but 
discharged home with mother (± 2 
days) , or close to it  Required NICU 
for more than 1 
week, and/or interventions (including 
surgery) leading 
to prolonged hospi[INVESTIGATOR_059] 
(report SAE)j  
Clinical AE in the newborn 
NOT identified elsewhere in this AE Grading Table  
(postmaturity
l) None  Symptoms causing 
no or minimal 
interference with 
usual functional 
activities  
 Symptoms causing 
greater than minimal 
interference with 
function and activities  
 Symptoms 
causing inability to perform 
functions  or 
activities  
 
  
Congenital anomalies/  
birth defectsm Variants of 
normal and minor anomalies are NOT reported, 
graded or 
followed  as AE, 
or SAEs.  They 
are collected in  
the database as 
part of the medical examination and 
reported in the 
Final Study 
Report.  N/A N/A Major congenital 
anomalies are reported as SAEs.   
Abbreviations and definitions:  
a Please refer to ‘Definitions of Safety Parameters’ for regulatory definition of ‘life threatening’ that requires reporting of  SAE.   
b Even if pregnancy loss does not require obstetrical care, and is a natural outcome of n on-viable conception, psychological 
events around the event require recognition especially in research subject s.  
c EBL:  Estimated blood loss.  
d TOA:  Tubo -ovarian abscess.  
e For preterm delivery, report two AEs: one for mother and one for infant. Unless specified otherwise in the protocol, only one 
neonatal AE will be reported for all preterm birth -related problems. Additional AEs will be reported only if infant has unexpected 
AEs: surgery, congenital anomalies, etc.   
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          82 
 f Examples of complications of deliv ery that would meet AE/SAE reporting are: maternal death, stillbirth, bleeding placenta 
previa or abruption that required emergency delivery, etc.  
g Preterm birth and low birth weight carry different risks and will be reported separately (or twice if an i nfant is both preterm and 
low birth weight). If gestational age is not known, only birth weight will be reported. Infants will be plotted on the approp riate 
growth scale for the population being studied and percentage of ‘appropriate’, ‘large’, or ’small f or gestational age’ infants will 
be reported in the final study report.  
h Examples: transient tachypnea, hypothermia, cephalo -hematoma, bruising. Admitted to normal nursery or observed for less than 
one day in NICU/SCN.  
i Examples: admission to NICU/SCN for physiological causes like hyperbilirubinemia requiring phototherapy, hypoglycemia, 
suspected but ruled out congenial infection, oxygen via nasal cannula, or NCPAP.  
j Examples: confirmed neonatal infection:  bacterial, viral, fungal sepsis, meconium aspi[INVESTIGATOR_452355], severe 
laboratory, or/and clinical signs and symptoms.  
k Examples: perinatal asphyxia: [ADDRESS_576783] -maturity.  
m Investigators should consult the protocol and/or the MOP for a list of ‘major congenital anomalies’ and report them as SAE. 
Minor anomalies (also listed in the protocol and/or MOP) are structural findings that do not have surgical, medical or cosmetic 
importance. Minor physical features that typi[INVESTIGATOR_452356] 4% of newborn infants are considered ‘variants’ of norm al, 
while ‘minor anomalie s’ occur in less than 4% of infants. If in doubt: review referenced articles in Rasmussen et al Clin Infect 
Dis 2014 p S 428ff29  and/or consult DMID.  
AE:  Adverse Events  
CS:  Cesarean Section  
HELLP syndrome:  Group of symptoms that occur in pregnant women who have: hemolysis (H); elevated liver enzymes (EL); 
low platelet count (LP).  
9.2.5. Serious Adverse Events  
Serious Adverse Event (SAE):   An adverse event or suspected adverse reaction is considered  
“serious” if, in the view of either the site principal investigator [INVESTIGATOR_10157], it results in any of the 
following outcomes: 
• Death , 
• a life -threatening adverse event* , 
• inpatient hospi[INVESTIGATOR_1081] , 
• a persistent or s ignificant incapacity or substantial disruption of the ability to conduct 
normal life functions, or 
• a congenital anomaly/birth defect¥. 
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical 
judgment they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          83 
 *Life -threatening adverse event. An adverse event is considered “life -threatening” if, in the view 
of either the site principal investigator [INVESTIGATOR_10157], its occurrence places the patient or subject  at 
immediate risk of death. It does not include an adverse event that, had it occurred in a more 
severe form, might have caused death.  
 
¥Congenital anomalies will be reported as described under Section 9.1. 
SAEs will be: 
• Assessed for severity and relationship  to study product and alternate etiology (if not 
related to study product) by a licensed study physician listed on the Form FDA [ADDRESS_576784] a 
study clinician. The study clinician will either visit the participant at home or the 
participant will be ref erred to the study health center based on the FW’s assessment.  
• Recorded on the appropriate SAE data collection  form and eCRF. 
• Followed through resolution by a licensed study physician listed on the Form FDA 1572 as the site principal investigator [INVESTIGATOR_11637] -investigator. 
• Reviewed and evaluated by [CONTACT_202421] (ISM) ( as deemed necessary 
per Section 9.6.1), the DSMB (periodic review unless related), DMID, and the IRB, as 
required by [CONTACT_452444]. 
9.2.6. Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings  
The site principal investigator [INVESTIGATOR_29353]-investigator is responsible for recording all 
AE/SAEs that are observed or reported during this trial, as described in this protocol, regardless of the relationship to study product. AE/ SAEs, or abnormal clinical findings will be collected, 
assessed, documented, reported, and followed appropriately. 
9.3. Reporting Procedures  
Solicited injection site and systemic reactogenicity events for pregnant women will be documented and reported from the time of each study vaccination through 7 days after the study 
vaccination.  
Unsolicited non-serious AEs for pregnant women will be documented and reported from the time 
of study vaccination through approximately 30 days after the study vaccination (Day [ADDRESS_576785], for pregnant women). 
DMID Protocol 16- [ADDRESS_576786] be submitted immediately 
(within 24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance 
Group, at the following address: 
DMID Pharmacovigilance Group 
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_576787]. Suite 650 
Bethesda, MD [ZIP_CODE], [LOCATION_003] 
SAE Hot Line: 1 -[PHONE_889] (US) or [PHONE_2619] (outside US) 
SAE FAX Number: 1 -[PHONE_1729] (US) or [PHONE_2621] (outside US) 
SAE Email Address: [EMAIL_1393]  
In addition to the SAE form, select SAE data fields must also be entered into the DCC ’s 
Advantage eClinical. Please see the protocol -specific MOP for details regarding this procedure. 
Other supporting documentation of the event may be requested by [CONTACT_295051]. 
The site will send a copy of the SAE report(s) to the ISM (as deemed necessary  per Section 
9.6.1) when they are provided to the DMID Pharmacovigilance Group. The DMID Medical 
Monitor and DMID Clinical Project Manager will be notified of the SAE by [CONTACT_168754]. The DMID Medical Monitor will review and assess the SAE for regulatory reporting and potential impact on study subject safety and protocol conduct. At any time after completion of the study, if the site principal investigator [INVESTIGATOR_29353]-
investigator becomes aware of an SAE that is suspected to be related to study product, the site principal investigator [INVESTIGATOR_29353]- investigator will report the event to the DMID 
Pharmacovigilance Group.  
9.3.2. Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  
Following notification from the investigator, DMID, the Investigational New Drug (IND) sponsor, will report any suspected adverse reaction that is both serious and unexpected. DMID will report an adverse event as a suspected adverse reaction only if there is evidence to suggest a 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          85 
 causal relationship between the drug and the adverse event. DMID will notify FDA and all 
participating investigators (i.e., all investigators to whom the sponsor is providing drug under its 
IND(s) or under any principal investigator’s IND(s)) in an IND safety report of potential serious 
risks from clinical trials or any other source, as soon as possible, but in no case later than 15 calendar days after the sponsor determines that the information qualifies for reporting as specified in 21 CFR Part 312.32. DMID will also notify FDA of any unexpected fatal or life-
threatening suspected adverse reactio n as soon as possible, but in no case later than 7 calendar 
days after the sponsor’s initial receipt of the information. Relevant follow up information to an 
IND safety report will be submitted as soon as the information is available. Upon request from FDA , DMID will submit to FDA any additional data or information that the agency deems 
necessary, as soon as possible, but in no case later than [ADDRESS_576788].  
All serious events designated as “not related” to study product(s), w ill be reported to the FDA at 
least annually in a summary format.  
9.4. Type and Duration of Follow -up of Subjects after Adverse Events  
Non-serious AEs will be collected, assessed, and followed through resolution from the time of 
study vaccination through approximately 30 days after study vaccination. For pregnant women, this period extends from vaccination until Day 31 or delivery, whichever occurs earlier. All 
unresolved non-serious AEs will be followed through resolution even if this extends beyond the 
study-reporting period. SAEs and new-onset chronic medical conditions will be collected, assessed, and followed from 
the time of study vaccination through resolution even if this extends beyond the study- reporting 
period. The reporting period extends from vaccination until 6 months postpartum (180 days of 
life for the infant visit) for pregnant women. Resolution of an AE/SAE is defined as the return to pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
Follow-up procedures, evaluations, and outcomes will be recorded on the appropriate data 
collection form.  
9.5. Halting Rules  
For pregnant women, further enrollment and study vaccinations will be halted for DSMB review/recommendation if any of the following are reported: 
• Any subject experiences ulceration, abscess, or necrosis at the injection site related to 
study product administration. 
• Any subject experiences laryngospasm, bronchospasm, or anaphylaxis within [ADDRESS_576789]. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          86 
 • Two or more subject s experience generalized urticaria within [ADDRESS_576790]. 
• Any subject experiences a study vaccine -related SAE from the time of study vaccination 
through subject ’s last study visit.  
• Any subject experiences acute weakness of limbs and/or cranial nerve innervated muscles 
(description of potential signal of GBS) after administration of s tudy vaccine.  
For pregnant women, this study will also be halted for DSMB review/recommendation if, within 7 days after administration of the study vaccination, any of the following occurs: 
• 5% or more of subject s (with a minimum of 5 subjects) who received  study vaccine 
experience the same severe (Grade 3) study vaccine- related injection site reaction.  
• 5% or more of subject s (with a minimum of 5 subjects) who received study vaccine 
experience the same severe (Grade 3) study vaccine- related subjective systemic reaction 
with the exception of allergic reaction, for which the severity (grade) is corroborated by [CONTACT_3462]. 
• 5% or more of subject s (with a minimum of 5 subjects) who received study vaccine 
experience the same severe (Grade 3) study vaccine- related quantitative systemic 
reaction.  
• 5% or more of subject s (with a minimum of 5 subjects) who received study vaccine 
experience the same severe (Grade 3) pregnancy -related AEs, as found in Section 9.2.4, 
that are deemed study -vaccine related.  
Grading scales for solicited local (injection site) and systemic (subjective and quantitative) 
reactions are included in Section 9.2.2. Solicited injection site measurements will not be used to 
halt the study.  
If any of the halting rules are met following any subject  receipt of study vaccination, then this 
study will not continue with the remaining enrollments or study vaccinations without a review by 
[CONTACT_421260]. DMID retains the authority to suspend additional enrollment and study interventions/ administration of study product during the enti re study, as applicable.  
9.6. Safety Oversight (ISM plus SMC or DSMB)  
9.6.1. Independent Safety Monitor (ISM)  
The ISM is a physician with relevant expertise whose primary responsibility is to provide independent safety monitoring in a timely fashion. Participation is for the duration of the trial 
and is a voluntary position that does not receive payment. The ISM must meet the requirements 
of the NIAID conflict of interest policy.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          87 
 The ISM:  
• Will have experience in obstetrics.  
• Is in close proximity to the study site and has the authority and ability to readily access 
subject  records in real time.  
• May be a member of the participating institution’s staff but preferably be from a different 
organizational group within the institution. 
• Should not be in a direct supervisory rela tionship with the investigator.  
• Should have no direct involvement in the conduct of the study. 
The ISM will: 
• Sign a Conflict of Interest (COI) certification at the time they are asked to participate and 
provide updates to this information as needed. 
• Receive reports of Serious Adverse Events (SAEs)  deemed related to the study  from the 
site investigator and will be notified by [CONTACT_295052].  
• Receive reports from the site investigator of any subject who experiences acute weakness  
of limbs and/or cranial nerve innervated muscles (description of potential signal of GBS) 
after administration of study vaccine.  
• Evaluate the SAE and report their clinical assessment to DMID, through DMID- CROMS 
SOCS in a timely manner using the attached r eport form and email the report to DMID-
CROMS SOCS.  
• Communicate with the investigator at the participating site as needed.  
• Review additional safety related events at the request of DMID.  
• Provide additional information to DMID and/or the DSMB by [CONTACT_452445].  
9.6.2. Data and Safety Monitoring Board (DSMB) 
Safety oversight will be conducted by a DSMB that is an independent group of experts that 
monitors subject  safety and advises DMID. The DSMB members will be separate and 
independent of study personnel participating in this trial and should not have scientific, financial, 
or other conflicts of interest related to this trial. The DSMB will consist of members with appropriate expertise to contribute to the interpretation of the data from this trial.  
The DSMB will operate under the rules of a DMID -approved charter that will be written at the 
organizational meeting of the DSMB. Procedures for DSMB reviews/meetings will be defined in the charter. Reports may include enrollment and demographic information, medical history, 
concomitant medications, physical assessments, clinical laboratory values, dosing compliance, 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          88 
 and solicited and unsolicited AE/SAEs. The DSMB will review SAEs on a regular basis and ad 
hoc during this trial. The DMID Medical Monitor and the ISM (as deemed necessary  per Section 
9.6.1) will be responsible for reviewing SAEs in real time.  
Additional data may be requested by [CONTACT_4318], and interim statistica l reports may be generated 
as deemed necessary and appropriate by [CONTACT_122830]. The DSMB may receive data in aggregate and presented by [CONTACT_2939] (pregnant women, infants). The DSMB may also be provided with 
expected and observed rates of the solicited AEs in an unblinded fashion and may request the 
treatment assignment be unblinded for an individual subject  if required for safety assessment. 
The DSMB will review grouped and unblinded data in the closed session only. As an outcome of 
each review/meeting, the DS MB will make a recommendation as to the advisability of 
proceeding with study vaccinations (as applicable), and to continue, modify, or terminate this trial. 
The DSMB will conduct the following reviews: 
• When safety data collected through Day 8 is available for 25% of pregnant study 
subjects.  
• Ad hoc when a halting rule is met or DMID/DSMB chair may convene an ad hoc meeting 
if there are immediate concerns regarding observations during this trial.  
• Final review meeting: [ADDRESS_576791] s’ protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, ICH/GCP guidelines, and applicable regulations, and th at this trial is 
conducted in accordance with the protocol, protocol-specific MOP, and applicable sponsor standard operating procedures. DMID, the sponsoring agency, or its designee will conduct site-
monitoring visits as detailed in the clinical monitoring  plan. 
Site visits will be made at standard intervals as defined by [CONTACT_149098]. Monitoring visits will include, but are not limited to, review of 
regulatory files, accountability records, eCRFs, informed consent forms, medical and laboratory 
reports, and protocol and GCP compliance. Site monitors will have access to each participating VTEU site, study personnel, and all study documentation according to the DMID-approved site monitoring plan. Study monitors will meet with site principal investigators to discuss any 
problems and actions to be taken and document visit findings and discussions. 
DMID Protocol 16- [ADDRESS_576792] of maternal antibody on primary infant 
immune responses to DTwP, identifying cofactors associated with infant and maternal immune responses and determining immune responses in colostrum/breast milk. 
11.1. Study Hypotheses  
BOOSTRIX will be safe and well tolerated in pregnant women and will lead to PT levels that are higher in the pregnant women and their infants as compared to pregnant women vaccinated with a Td vaccine and their infants. This is one of the first stud ies of maternal Tdap vaccination in a 
low resource setting in Africa , and where infants received whole cell, rather than acellular 
pertussis vaccinations. Thus, this study is intended to obtain preliminary estimates of immune response in this setting; it is not designed to test a formal hypothesis.  
11.2. Sample Size Consideratio ns 
11.2.1. Study Design  
This is a phase II, randomized, double-blind, active-controlled study in which 200 healthy pregnant women, ages 18 through 39 years, inclusive, will be randomly allocated in a 2:1 ratio to 
receive either Tdap (BOOSTRIX) or Td at 14 0/7 week s through 26 6/[ADDRESS_576793] that the sites will be able to enroll this study in a timely fashion. Prior experience suggests up to 15% of subject s may 
be excluded from the per protocol analysis for the primary immunogenicity outcome either because they were lost -to-follow-up or otherwise do not have data available following the study 
vaccination, or because they had a protocol deviation requiring their exclusion from the per protocol analysis. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          91 
 11.2.3. Sample Size  
The study is planned to enroll 200 pregnant women (133 BOOSTRIX, 67 Td). 
This will be one of the first studies  of maternal Tdap vaccination in an African, low resource 
setting, and where infants received whole cell, rather than acellular pertussis vaccinations . Thus, 
this study is intended to obtain preliminary estimates of immune response in this setting; it is not 
designed to test a specific null hypothesis. The tables below describe the power to detect safety events and the precision available for estimating  immune response for the planned sample size. 
Table 9 indicates the probability of observing one or more safety event, such as solicited 
injection site or systemic symptom, or an unsolicited adverse event of a particular type within a treatment arm. 
Table 9: Power (%) to Detect Safety Events  
Event  
Frequency  N = 133 N = 67 
≥0.01%  
Rare  1.3 <1 
≥0.1%  
Uncommon 12.5 6.5 
 ≥1%  
Common 73.7 49.0 
≥10%  
Very 
Common 100.0 99.9 
In addition to safety, as a co- primary objective , the study will assess serum  PT antibody at birth 
among infants whose mothers received a single dose of BOOSTRIX, and as secondary and 
exploratory objective s, the study will assess maternal and infant humoral re sponse to all vaccine 
antigens. Immune response wi ll be measured by [CONTACT_6428]. Table 10 presents the precision (95% 
CI) available for estimating GMC of ELISA titers against the vaccine component using assumptions for GMC and standard deviation (SD) for maternal and infant response to Tdap 
from Munoz et al. [13] and infant response post third dose of primary DTwP vaccine series from 
Ladhani et al.  [34] 
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          92 
 Table 10: Precision for Estimating GMC of ELISA Antibody Response 
 GMC   
SD 
(log-scale)  95% CI Estimate  
N = 133  N=[ADDRESS_576794] Dose DTwP (no maternal vaccination)  
PT 43.2 0.65 38.6 48.3 36.9 50.6 
FHA  41.1 0.66 36.7 46.1 35.0 48.3 
FIM 224.9  0.97 190.2  265.9  177.2  285.4  
Table 11 presents the minimum difference in infant PT antibody GMC at birth between the Td 
and Tdap (BOOSTRIX) vaccination arms that would be detectable with 80% power. The 
assumed GMC and SD used for these calculations are based on the PT antibody GMC and SD 
observed at birth in infants whose mother received either Tdap or placebo vaccination during pregnancy, reported in Munoz et al. [13]. The calculations are based on a two -sided two sample 
T-test to compare means, with alpha = 0.05. 
  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          93 
 Table 11: Minimum Detectable Difference in Infant PT Antibody GMC  at Birth 
Comparing Infants Born to Mothers Vaccinated with BOOSTRIX versus Td  
Td Tdap  
(BOOSTRIX)  Assumed GMC  
(BOOSTRIX)  Maximum GMC 
Detectable with Power = 
0.8 
(Td) Minimum Detectable 
Difference  
(BOOSTRIX - Td) 
N=67  N=[ADDRESS_576795]. Any ad-hoc analyses, jointly developed by [CONTACT_452446]/or University 
of Maryland , will be executed by [CONTACT_394450].  
None of the interim analyses will include any formal statistical hypothesis testing; therefore, p -
value ad justment will not be made to any analyses . 
11.3.1. Interim Safety Review  
An interim safety review will occur when safety data collected through Day 8 is available for 25% of pregnant study subject s. Reports for interim safe ty reviews will include data for pregnant 
participants , and any infants born at the time of data cutoff. Summaries may include enrollment 
and demographic information, medical history, concomitant medications, physical assessments, and solicited and unsolicited AE/SAEs. Additional data may be requested by [CONTACT_452447] 9.6.2. 
This trial will be monitored to determine if any of the halting rules desc ribed in Section 9.5 are 
met. 
11.3.2. Interim Immunogenicity or Efficacy Review  
An interim immunogenicity review is not planned. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          94 
 11.4. Final Analysis Plan  
A formal statistical an alysis plan will be developed and finalized prior to database lock. 
11.4.1. Analysis Populations 
The Safety Analysis population includes all pregnant women who received the study 
vaccination, and all infants born during the study. 
The maternal intent -to-treat (ITT ) population for immunogenicity analyses includes all pregnant 
women who received the study vaccination. The maternal per -protocol (PP) population for immunogenicity analyses includes all subject s in 
the ITT subset with the following exclusions: 
• Data from all available visits for subject s: 
• Found to be ineligible at baseline. 
• Without results from the baseline visits.  
• Without results from at least one post- vaccination visit.  
• Data from all visits subsequent to major protocol deviations, such as: 
• Receipt of non-study licensed vaccine within the pre-specified exclusion windows 
(Section 5.2). 
• Receipt of immunosuppressive therapy (e.g., corticosteroids) within 30 days prior to 
or after study vaccination.  
• Data from any visit that occurs substantially out of window. 
The infant ITT population for immunogenicity analyses includes all infants born to women who 
received the study vaccination.  
The infant PP population for primary and secondary  immunogenicity analyses includes all 
infants in the ITT subset who have a blood sample from the perinatal period (cord blood or drawn blood within the 72 hours after birth). The infant PP population for exploratory  immunogenicity analyses includes all infants in the ITT 
subset with the following exclusions: 
• Infants who did not receive DTwP within appropriate window. 
• Infants who received any product that would impact immune response. 
• Infants with blood samples captured substantially out of window. 
In the case of mis -randomization, subject s will be analyzed according to the study product 
actually received for all analysis populations. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          95 
 11.4.2. Safety Data 
Maternal safety and tolerability, and fetal/infant outcomes will be summarized for the Safety 
Analysis Population. Solicited AEs will be summarized by [CONTACT_452448] [ADDRESS_576796] severe response over the follow-up period, dichotomizing into a binary variable (none versus mild, moderate, or severe) and using standard techniques, such as exact confidence 
intervals, to summarize the proportion of subjects reporting each symptom, any injection site 
symptom, and any systemic symptom.  
Unsolicited AEs will be coded by [CONTACT_10607] (MedDRA
) for 
preferred term and system organ class (SOC). The number of SAEs is expected to be small in 
this trial, so these events will be reported by [CONTACT_394446], 
MedDRA preferred term and SOC, date of study vaccination, event date, severity, relatedness, 
and outcome for each event. Non-serious unsolicited AEs will be summarized as number and percentage of subject s reporting at least one event in each MedDRA
 preferred term and SOC, 
tabulated by [CONTACT_134274]. Additionally, the proportion of subject s 
and exact 95% confidence intervals of AEs in aggregate and by [CONTACT_61132] categories will be 
computed. 
The proportion of subject s reporting solicited or unsolicited AEs may be compared between 
treatment arms using  Fisher’s exact test. The number of untoward fetal outcomes, perinatal 
complications, and major congenital abnormalities is expected to be small and so these events 
will be reported by a detailed listing including the event description, MedDRA preferred term 
and SOC, relevant dates (study vaccination and AEs), severity, relatedness, and outcome for 
each event. If more than 5% of pregnant women experience untoward fetal outcomes, perinatal complications, or infants born with major congenital abnormalities, the proportion of subject s 
with such events will be compared between the BOOSTRIX and Td treatment arms using 
Fisher’s Exact test.  
11.4.3. Immunogenicity Data (ELISA) 
Immunogenicity data summaries and analysis for pregnant women will be presented for the ITT 
and the PP populations. Immunogenicity data summaries and analysis for infants will be 
presented for the infant ITT and infant PP populations. 
Immune responses will be reported for antibodies against each of the antigens in the vaccine and at each time point fo r each subject  group- pregnant women receiving BOOSTRIX, pregnant 
women receiving Td, and the infants of women who received BOOSTRIX or Td while pregnant. 
GMC and corresponding 95% confidence intervals will be reported. 
For each antigen, GMC will be compar ed between treatment arms using a t -test on log-
transformed ELISA titers.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          96 
 The level of antibody transplacentally transferred will be summarized as the Geometric Mean 
Ratio (GMR), with corresponding 95% confidence interval, of mother’s concentration to infa nt’s 
concentration for all mother-infant pairs for which both the mother and infant have data at the 
applicable time point (delivery/birth).  
Graphical presentations of immune response may include reverse cumulative distribution (RCD) 
curves, and longitudinal presentations of GMTs. 
To evaluate the association with of maternal immunogenicity cofactors, Maternal and Infant anti-
PT ELISA response will be summarized stratified by [CONTACT_452449] (18 -29, 30-39 years old), 
parity (primiparous vs. multiparous), GA at time of vaccination (14 -17, 18-21, 22-26 weeks), GA 
at time of delivery (28 -32, 33-36, 37 or more weeks), and infant birthweight, and these cofactors 
will be evaluated in regression modeling. Antibody responses in breast milk/colostrum will be evaluated in a similar way to above.  
Additional exploratory analyses, including analysis of cytokine response will be described in the statistical analysis plan.  
11.4.4. Missing Values and Outliers  
All attempts will be made to collect all data per protocol. As missing data ar e expected to be 
minimal, no imputation will be performed for missing values. Any data point that appears to be erroneous or inexplicable based on clinical judgment will be investigated as a possible outlier. If 
data points are identified as outliers, sens itivity analyses will be performed to examine the 
impact of including or excluding the outliers. Any substantive differences in these analyses will 
be reported. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          97 
 12. SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA/DOCUMENTS 
Each participating VTEU site (or subcontracted site) will maintain appropriate medical and 
research records for this trial, in compliance with ICH E6, Section 4.9, and regulatory and 
institutional requirements for the protection of confidentiality of subjects. Each participating 
VTEU site will permit authorized representatives of the DMID, its designees, and appropriate 
regulatory agencies to examine (and when required by [CONTACT_1289]) to copy clinical trial records for the purposes of quality assurance reviews, audits, monitoring and evaluation of the trial safety and progress. These representatives will be permitted access to all source data, which include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, 
memoranda, evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives, microfilm or magnetic media, x -rays, and subject  files and 
records kept at the pharmacy, at the laboratories, and medico-technical departments involved in 
this clinical trial. Source data are all information, original records of clinical findings, 
observations, or other activities in a clinical trial necessary for the rec onstruction and evaluation 
of the trial.  
Interview of subject s is sufficient for obtaining medical history. For pregnant women, it is 
expected that certain source data, such as gestational age and diagnosis of high risk obstetrical conditions, will be extracted from the antenatal record. In the event of the need to obtain 
information for the evaluation of eligibility or safety, the research team may, with the permission 
of the subject  via the consent process, obtain that information from the medical chart. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          98 
 13. QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, each participating VTEU site 
and its subcontractors are responsible for conducting routine quality assurance (QA) and quality 
control (QC) activities to internally monitor study progress and protocol compliance. The site 
principal investigator [INVESTIGATOR_71464]- related sites, source data/data 
collection forms, and reports for the purpose of monitoring and auditing by [CONTACT_456], and 
inspection by [CONTACT_3482]. The site principal investigator [INVESTIGATOR_366454]. The DCC will implement quality control procedures beginning with the data entry system and generate data quality control checks that will be run on the database. Any missing data or data 
anomalies will be communicated to the site(s) for clarification and resolution.  
DMID -designated clinical monitors will verify that the clinical trial is conducted and data are 
generated, documented (recorded), and reported in compliance with the protocol, ICH/GCP guidelines, and the applicable regulatory requirements. Clinical monitor ing reports will be 
submitted to DMID.  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          99 
 14. ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.1. Ethical Standard  
The site principal investigator [INVESTIGATOR_452357]: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research (National Commission for the Protection of Human Subjects of Biomedical 
and Behavioral Research [April 18, 1979]) and codified in [ADDRESS_576797]  
Each site principal investigator [INVESTIGATOR_452358]/her research site(s) and send supporting documentation to the DMID before initiating 
recruitment of subjects. The investigator will submit applicable information to the IRB/IEC on 
which it relies f or the review, to conduct the review in accordance with 45 CFR 46, ICH E6 
GCP, and as applicable,  21 CFR 56 (Institutional Review Boards) and 21 CFR 50 (Protection of 
Human Subjects), other federal, state, and local regulations. The  IRB/IEC must be registe red 
with the Office for Human Research Protections (OHRP ) [OHRP -only  or OHRP/FDA ] as 
applicable to the research. DMID  must receive the documentation that verifies IRB/IEC-approval 
for this protocol, associated informed consent documents, and upon request any recruitment 
material and handouts or surveys intended for the subjects, prior to the recruitment and 
enrollment of subjects. 
Any amendments to the protocol or consent materials will be approved by [CONTACT_1201]/IEC before 
they are implemented. IRB/IEC review  and approval will occur at least annually throughout the 
enrollment and follow-up of subjects and may cease if annual review is no longer required by 
[CONTACT_5279]. The investigator will notify the IRB/IEC of deviations from the protocol 
and reportable SAEs, as applicable to the IRB/IEC policy. 
Each institution engaged in this research will hold a current Federalwide Assurance (FWA) 
issued by [CONTACT_299147]. 
14.3. Informed Consent Process  
Specifically, prior to obtaining individual informed consent for each subject, the investigators will discuss the trial with all the appropriate community associations and leaders, as necessary, to obtain permission to approach the prospective subject s. After community permission is granted, 
written,  informed consent for participation in the trial will be obtained by [CONTACT_452450] s. The consent forms will be written in English; French, the official 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          100 
 language of Mali; and Bambara, the most prevalent of the local Malian la nguages. The consent 
documents will be recorded on audiotape, in order to allow Malian prospective subject s who may 
not be able to read English, French, or Bambara to hear the consent document verbatim in the 
language of their choice.  
The site principal investigator [INVESTIGATOR_452359] s in accordance with the eligibility criteria 
detailed in Section 5. Before any study procedures are performed, subject s must sign (or, as is 
customary in Mali, consent may be indicated using a fingerprin t) an informed consent form that 
complies with the requirements of 21 CFR Part 50 and 45 CFR 46 and the local IRB. 
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continues throughout the individual’s trial participation. Before any study procedures 
are performed, including screening of subject s for eligibility, subject s will receive a 
comprehensive explanation of the proposed study procedures and study interventions/products, 
including the nature and risks of this trial, alternate therapi[INVESTIGATOR_014], any known AEs, the investigational status of the components, and the other elements that are part of obtaining proper 
informed consent. Subjects will also receive a detailed explanation of the proposed use and 
disclosure of their protected health information, including specifically their serum samples. Subject s will be allowed sufficient time to consider participation in this trial, after having the 
nature and risks of this trial explained to them and have the opportunity to discuss this trial with their family, friends, or others or think about it prior to agreeing to par ticipate.  
The consent process of the pregnant subject will also include permission for inclusion of the infant in the postpartum phase of the study. After participants have given birth, study personnel 
will review the infant participation with them. After this review, participants will reaffirm their 
consent for their infants to take part in the post-partum phase of the study by [CONTACT_452451]. If this page is not signed, it is assumed that consent is not 
given and the infant will not participate in the post-partum phase of the study. Separate 
permission from the father of the infant will not be required, unless individual IRBs or Research Ethics Committees require it. Subject  understanding of the study is determined by [CONTACT_941] r esearch 
team member who is performing the informed consent process by [CONTACT_452452] . No formal Evaluation to Sign Consent or 
Comprehension Questionnaire will be used. 
For illiterate subjects, the consent document will be provided on audiotape with verbatim reading 
of the consent document in the language understandable to the subject . For illiterate pregnant 
women, even if the father of the baby [CONTACT_452453], the pregnant woman will provide permission. 
Whenever possible, the father of the baby [CONTACT_452454], but his 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          101 
 signature/ fingerprint to confirm permission for the infant participation will not be required, 
unless the local IRB/Research Ethics Committee requires it.  
The consent pr ocess for illiterate subject s will require that an impartial witness is present during 
the consent process and that the witness signs and dates the consent form. The witness must 
speak the language in which consent is obtained and must not be a key personnel member in the 
study.  
Informed consent forms describing in detail the study interventions/products, study procedures, risks, and possible benefits will be given to subjects. The informed consent form will not include any exculpatory statements. Informed consent forms will be IRB-approved and prospective 
subject s will be asked to read and review the appropriate document. Upon reviewing the 
appropriate document, the site principal investigator (or designee) will explain the research study to prospective subject s and answer any questions that may arise. Prospective subject s, if willing 
to join the study, will sign or fingerprint the informed consent form. Written documentation of the informed consent process will occur prior to starting any study procedures or interventions, 
including administering study product. 
DMID will provide the site principal investigator, in writing, any new information that 
significantly impacts subject  risk of receiving the investigational product. This new information 
will be communicated by [CONTACT_16541] [INVESTIGATOR_452360]. The informed consent document will be updated, and subject s will be re -consented per IRB requirements, if necessary.  
Study p ersonnel may employ IRB -approved recruitment efforts prior to obtaining subject  
consent; however, before any study procedures are performed to determine protocol eligibility, an informed consent form must be signed or fingerprinted . Subject s will be given a copy of all 
their signed or fingerprinted  informed consent forms. 
The process of confirming on- going willingness to participate in the study will be documented 
on templated source documentation records. Subject s will be asked at visits through the study 
about their willingness to continue to provide consent for participation. 
The rights and welfare of subject s will be protected by [CONTACT_452455] s that the quality of 
their medical care will not be adversely affected if they decline to participate in or withdraw 
from this trial.  
14.3.1. Informed Consent/Assent Process (in Case of a Minor)  
N/A 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          102 
 14.4. Exclusion of Women, Minorities, and Children (Special Populations)  
This trial will be inclusive of all persons who meet the Subject  Inclusion and Exclusion Criteria, 
regardless of religion, or ethnic background. Men are excluded because the study involves the 
evaluation of a vaccine for pregnant women. Given that this is the first formal study of 
BOOSTRIX in pregnant women in Mali, adolescent women who are pregnant will not be enrolled, only women 18 to 39 years old. In addition, women over age 39 years are being excluded because of the small increased risk of adverse pregnancy and fetal/infant outcomes in 
older women. 
14.5. Subject Confidentiality 
Subject s will have code numbers and will not be identified by [CONTACT_2300]. Subject  confidentiality is 
strictly held in trust by [CONTACT_452456], their study personnel, the sponsor(s), and their agents. This confidentiality is extended to cover testing of biological 
samples, in addition to the clinical information relating to subject s. 
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning this trial or the data will be released to any 
unauthorized third party without prior written approval of the DMID and the subject. Subject confidentiality will be maintained when study results are published or discussed in conferences.   All information p rovided by [CONTACT_452457] (other than a subject ’s medical records) will be kept 
confidential by [CONTACT_16541] [INVESTIGATOR_421226]. This information and data will not be used by [CONTACT_16541] [INVESTIGATOR_452361]. These restrictions do not apply to the 
following: (1) information which becomes publicly available through no fault of the site 
principal investigator [INVESTIGATOR_29355]; (2) information which is necessary to disclose in confidence to an IRB solely for the evaluation of this trial; (3) information which is necessary to 
disclose in order to provide appropriate medical care to a trial subject ; or (4) study results which 
may be published as described in Section 16. 
The study monitor, applicable regulatory authorities, such as the FDA, or other authorized 
representatives of the sponsor may inspect all documents and records required to be maintained 
by [CONTACT_16541]. This includes, but is not limited to, medical records (office, 
clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subject s in this trial. Each participating VTEU 
site will permit access to such records.  
To protect privacy, we have received a Certificate of Confidentiality.  With this Certificate, the researchers cannot be forced to release information that may identify the research subject, even by a court subpoena, in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings.  The researchers will use the Certificate to resist any d emands for information 
that would identify the subject, except as explained below. 
DMID Protocol 16- [ADDRESS_576798] a demand for information from personnel of the United 
States (US) Government that is used for auditing or evaluation of federally funded projects, like 
this study, or for information that must be released in order to meet the requirements of the US 
Food and Drug Administration (FDA). 
A Certificate of Confidentiality does not prevent the subject from voluntarily releasing 
information about themselves or their involvement in this research.  If any person or agency 
obtains a written consent to receive research information, then the researchers may not use the 
Certificate to withhold that information.  
The Certificate of Confidentiality do es not prevent the researchers from reporting without the 
subject’s consent, information that would identify the subject as a participant in the research 
project regarding matters that must be legally reported including: child and elder abuse, sexual 
abuse, or wanting to harm themselves or others. 
The Certificate of Confidentiality applies only under US law and does not apply to Malian 
courts. 
14.6. Study Discontinuation  
If the study is prematurely terminated by [CONTACT_456], any regulatory authority, or the inves tigator for any reason, the investigator will promptly inform the study subjects and assure 
appropriate therapy or follow -up for the subjects, as necessary. The investigator will provide a 
detailed written explanation of the termination to the IRB/IEC. If any subject’s private 
information will continue to be collected for this study, the IRB/IEC must approve a consent form with the study procedures, any risks and discomforts, and applicable elements, and the 
investigator or designee will re -consent the subjects as approved by [CONTACT_1201]/IEC. 
If this trial is discontinued, subject s who sign the informed consent form, and are randomized 
and vaccinated will continue to be followed for safety assessments. No further study vaccinations 
will be administered.  
14.7. Costs, S ubject Compensation, and Research Related Injuries 
There is no cost to subject s for taking part in this trial.  
Subject s may be compensated for their participation in this trial. Compensation will be in 
accordance with the local IRB’s policies and procedures, and subject to IRB approval. 
If it is determined by a participating VTEU site and the site principal investigator [INVESTIGATOR_270600] a subject  as a direct result of the tests or treatments that are done for this trial, then 
referrals to appropri ate health care facilities will be provided to the subject . Study personnel will 
try to reduce, control, and treat any complications from this trial. Immediate medical treatment may be provided by a participating VTEU site, such as giving emergency medications to stop immediate allergic reactions to the study vaccine. No financial compensation will be provided to 
DMID Protocol 16- [ADDRESS_576799]  by a participating VTEU site or the sponsor for any injury suffered due to 
participation in this trial.  
14.8. Future Use of Stored Specimens  and Data 
Subjects will be asked for their permission /refusal  to allow storage of their remaining samples 
for possible use in future research studies, such as examining additional immunological 
assessments or testing for antibodies against other viruses or bacteria. This permission is recorded on the consent document but separate from the consent for inclusion in the trial itself. 
These residual s amples will be stored for [ADDRESS_576800]. No human genetic tests will be performed on samples. Each sample will be encoded 
(labeled) only with a barcode and a unique tracking number to protect subject  confidentiality. If 
agreements regarding specimen transfer between institutions are required, such as Materials Transfer Agreements, the terms of those agreements will not contradict this protocol or the 
consent documents, and investigators will comply with the agreements. 
There are no benefits to subject s in the collection, storage, and subsequent use of their specimens  
for future research . Reports about future research done with subject ’s samples will NOT be kept 
in their health records. 
Subject s may be given the option to decide if they want their samples to be used for future 
research or have their samples destroyed at the end of this trial. The subject ’s decision can be 
changed  at any time prior to the end of this trial by [CONTACT_452458]. 
However, if the subject  originally consents to future use and subsequently changes her decision, 
any data from a previously collected sample may still be used for this re search.  
DMID Protocol 16- [ADDRESS_576801]  enrolled in this trial. All data collection forms will be completed 
in a neat, legible manner to ensure accurate interpretation of data. Black or blue ink will be used 
to ensure clarity of reproduced copi[INVESTIGATOR_014]. When mak ing a change or correction, study staff members 
will cross out the original entry with a single line and initial and date the change. Study staff 
members will not erase, overwrite, or use correction fluid or tape on the original. Data reported in the eCRF derived from the data collection forms will be consistent with the data 
collection forms or the discrepancies will be explained.  
The sponsor and/or its designee will provide guidance to site principal investigators and other study personnel on making corrections to the data collection forms and eCRF. 
15.1. Data Management Responsibilities  
All data collection forms and laboratory reports will be reviewed by [CONTACT_452459], who will ensure that they are accurate and complete.  Adverse ev ents will be 
recorded on the appropriate data collection form, assessed for severity and relationship, and 
reviewed by [CONTACT_16541] [INVESTIGATOR_29353] -investigator. 
Data collection is the responsibility of the study personnel at each par ticipating VTEU site under 
the supervision of the respective site principal investigator. During this trial, the site principal 
investigator [INVESTIGATOR_452362].  
The DCC for this trial will be responsible for data management, quality review, analysis, and reporting of the trial data.  
15.2. Data  Capture Methods 
Clinical (including, but not limited to, AE/SAEs, concomitant medications, medical history, and 
physical assessments), reactogenicity, and immunogenicity data wi ll be entered into a [ADDRESS_576802] protection and internal quality checks, such as automatic range checks, to identify data 
that appear inconsistent, incomplete, or ina ccurate. Clinical and reactogenicity  data will be 
entered directly from the data collection forms completed by [CONTACT_44518]. 
15.3. Types of Data  
Data for this trial will include clinical, safety, and outcome measures (e.g., clinical laboratory values, rea ctogenicity, and immunogenicity data).  
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          106 
 15.4. Timing/Reports  
Clinical, safety, reactogenicity and immunogenicity data will be analyzed once the last subject  
and last infant born to a pregnant subject  completes the final visit. Analyses will occur after all 
data h ave been entered, cleaned, and monitored, and the database locked. These analyses will be 
made available to the sponsor for planning subsequent trials and to the clinical investigators for 
publication. These analyses will not be used to make any decisions concerning the conduct of this trial.  
The clinical study report ( CSR) will be completed when all primary safety endpoint data and all 
primary immunogenicity endpoint data are available. Any available data from the secondary and exploratory immunogenicity endpoints may also be included. The CSR will be amended as 
additional secondary and exploratory immunogenicity endpoint data become available. 
Interim statistical reports may be generated as deemed necessary and appropriate by [CONTACT_122830]. Safety and immunogenicit y summary reports may be generated for the DSMB.  
Cumulative safety information, study status, and primary endpoint results may be presented at a 
public forum in a blinded manner or presented as summaries aggregated by [CONTACT_452460]. While the primary study is ongoing 
no data will be released that is unblinding at an individual subject level, and caution will be taken to ensure that data summarized by [CONTACT_452461]. Any ad-hoc analyses, jointly developed by [CONTACT_452446]/or University 
of Maryland , will be executed by [CONTACT_394450]. Publication of manuscripts may occur at 
the discretion of the sponsor in accordance with DMID’s Expanded Distribution of Clinical 
Research Endpoint Data Policy.  
15.5. Study Records Retention  
Study documents will be retained for a minimum of [ADDRESS_576803] , the site 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          107 
 principal investigator, or other study personnel. As a result of deviations, corrective actions are 
to be developed by [CONTACT_3483]. These practices are consistent with the following sections of ICH E6- 4.5: Compliance with 
Protocol, Sections 4.5.1, 4.5.2, and 4.5.3; 5.1: Quality Assurance and Quality Control, Section 
5.1.1; 5.20: Noncompliance, Sections 5.20.1, and 5.20.2. It is the responsibility of the site principal investigator [INVESTIGATOR_452363], or within five working days of the scheduled protocol- required activity. All 
deviations will be promptly reported to DMID, via the DCC’s Advantage eClinical. All protocol deviations, as defined above, will be addressed in study subject  data collection 
forms. A completed copy of the DMID Protoc ol Deviation Form will be maintained in the 
Regulatory File as well as in the subject 's chart. Protocol deviations will be sent to the local 
IRB/IEC per its guidelines. The site principal investigator [INVESTIGATOR_421228]. 
DMID Protocol 16- [ADDRESS_576804] submitted for them to the National 
Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/ ) an electronic 
version of their final, peer -reviewed manuscripts upon acceptance for publication, to be made 
publicly available no later than [ADDRESS_576805] be accessible to the  public on PubMed Central no later than 12 
months after publication. 
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/ 
• NIH Office of Extramural Research (OER) Grants and Funding, 
http://grants.nih.gov/grants/oer.htm 
As of January 2018, all c linical trials supported by [CONTACT_12242].gov, no later than [ADDRESS_576806] applied for certification of delayed posting.  
As part of the result posting a copy of this protocol (and its amendments) and a copy of t he 
Statistical Analysis Plan will be posted on ClincialTrials.gov.  
For this trial the responsible party is DMID which will register the trial and post results.  
The responsible party does not plan to  request certification of delayed posting. 
Refer to:  
• Publi c Law 110 -85, Section 801, Clinical Trial Databases 
• 42CFR11 
• NIH NOT -OD-16-149 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          109 
 17. LITERATURE REFERENCES 
1. Pertussis vaccines: WHO position paper. Wkly Epi[INVESTIGATOR_75313] 2010; 85(40): 385-400. 
2. 2012 Final Pertussis Surveillance Report. In: (U.S .) CfDCaP. Atlanta, GA: CDC, 2013. 
3. Burns DL, Meade BD, Messionnier NE. Pertussis resurgence: perspectives from the 
Working Group Meeting on pertussis on the causes, possible paths forward, and gaps in 
our knowledge. J Infect Dis 2014; [ADDRESS_576807] 1: S32-5. 
4. Clark TA. Changing pertussis epi[INVESTIGATOR_623]: everything old is new again. J Infect Dis 
2014; 209(7): 978-81. 
5. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis 
among infants in the [LOCATION_002], 1980-1999. JAMA 2003; 290(22): 2968-75. 
6. Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of 
pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis 2017; 17(9): 974-80. 
7. Barger -Kamate B, Deloria Knoll M, Kagucia EW, et al. Pertussis -Associated Pneumonia 
in Infants and Children From Low- and Middle- Income Countries Participating in the 
PERCH Study. Clin Infect Dis 2016; 63(suppl 4): S187-s96. 
8. Gkentzi D, Katsakiori P, Marangos M, et al. Maternal vaccination against pertussis: a systematic review of the recent literature. Archives of disease in childhood Fetal and neonatal edition 2017; 102(5): F456-f63. 
9. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and 
acellular pertussis vaccine (Tdap ) in pregnant women and persons who have or anticipate 
having close contact [CONTACT_452462] <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60(41): 1424-6. 
10. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis vaccine (Tdap) in pregnant women --Advisory Committee on 
Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62(7): 131-5. 
11. Gall SA, Myers J, Pi[INVESTIGATOR_63489] M. Maternal immunization with tetanus -diphtheria-
pertussis vaccine: effect on maternal and neonatal serum antibody levels. American journal of obstetrics and gynecology 2011; 204(4): 334.e1-5. 
12. Hardy -Fairbanks AJ, Pan SJ, Decker MD, et al. Immune responses in infants whose 
mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J 2013 ; 32(11): 
1257-60. 
13. Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus 
diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014; 311(17): 1760-9. 
14. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014; 384(9953): 1521-8. 
15. Skoff TH, Blain AE, Watt J, et al. Impact of the US Maternal Tetanus, Diphtheria, and 
Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation. Clin Infect Dis 2017. 
DMID Protocol 16- [ADDRESS_576808] Dis 1990; 161(3): 
487-92. 
17. Heininger U, Cherry JD, Christenson PD, et al. Comparative study of Lederle/[COMPANY_005] 
acellular and Lederle whole- cell pertussis -component diphtheria- tetanus -pertussis 
vaccines in infants in [LOCATION_013]. Vaccine 1994; 12(1): 81-6. 
18. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the 
serologic response and the incidence of adverse reactions aft er primary immunization 
with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995; 96(3 Pt 2): 580-4. 
19. Maertens K, Cabore RN, Huygen K, et al. Pertussis vaccination during pregnancy in 
Belgium: Follow -up of infants until 1 month after the fourth infant pertussis vaccination 
at 15 months of age. Vaccine 2016; 34(31): 3613-9. 
20. Abu Raya B, Srugo I, Kessel A, et al. The effect of timing of maternal tetanus, diphtheria, 
and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study. Vaccine 2014; 32(44): 5787-93. 
21. Eberhardt CS, Blanchard- Rohner G, Lemaitre B, et al. Maternal Immunization Earlier in 
Pregnancy Maximizes Antibody Transfer and Expect ed Infant Seropositivity Against 
Pertussis. Clin Infect Dis 2016; 62(7): 829-36. 
22. Cherry JD. Editorial commentary: the effect of Tdap vaccination of pregnant women on 
the subsequent antibody responses of their infants. Clin Infect Dis 2015; 61(11): 1645-7. 
23. Cushing AH, Samet JM, Lambert WE, et al. Breastfeeding reduces risk of respi[INVESTIGATOR_452364]. Am J Epi[INVESTIGATOR_5541] 1998; 147(9): 863-70. 
24. Yamakawa M, Yorifuji T, Kato T, et al. Long- Term Effects of Breastfeeding on 
Children's Hospi[INVESTIGATOR_452365]. Matern Child Health J 2015; 19(9): 1956-65. 
25. Kassim OO, Raphael DH, Ako-Nai AK, Taiwo O, Torimiro SE, Afolabi OO. Class-
specific antibodies to Bordetella pertussis, Haemophilus influenzae type b, Streptococcus pneumoniae and Neisseria meningitidis in human breast- milk and maternal -infant sera. 
Ann Trop Paediatr 1989; 9(4): 226-32. 
26. Abu Raya B, Srugo I, Kessel A, et al. The induction of breast milk pertussis specific 
antibodies following gestational tetanus -diphtheria-acellular pertussis vaccination. 
Vaccine 2014; 32(43): 5632-7. 
27. De Schutter S, Maertens K, Baerts L, De Meester I, Van Damme P, Leuridan E. 
Quantification of vaccine-induced antipertussis toxin secretory IgA antibodies in breast 
milk: comparison of different vaccination strategies in women. Pediatr Infect Dis J 2015; 
34(6): e149-52. 
28. Fedele G, Cassone A, Ausiello CM. T- cell immune responses to Bordetella pertussis 
infection and vaccination. Pathog Dis 2015; 73( 7). 
29. Warfel JM, Zimmerman LI, Merkel TJ. Comparison of Three Whole- Cell Pertussis 
Vaccines in the Baboon Model of Pertussis. Clin Vaccine Immunol 2015; 23(1): 47-54. 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          111 
 30. Huygen K, Cabore RN, Maertens K, Van Damme P, Leuridan E. Humoral and cell 
mediated  immune responses to a pertussis containing vaccine in pregnant and 
nonpregnant women. Vaccine 2015; 33(33): 4117-23. 
31. Pharmaceuticals G. BOOSTRIX package insert. Available at: 
https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Boostrix/pdf/BOOSTRIX.PDF.  
32. Limited BE. Diphtheria and Tetanus Vaccine (Adsorbed, Reduced Antigen(s) Content). 
Available at: https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav=0&ID=280. Accessed 12/18/2017. 
33. Rasmussen SA, Hernandez -Diaz S, Abdul- Rahman OA, et al. Assessment of congenital 
anomalies in infants born to pregnant women enrolled in clinical trials. Clin Infect Dis 2014; [ADDRESS_576809] 7: S428-36. 
34. Ladhani SN, Andrews NJ, Southern J, et al. Antibody responses after primary 
immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. Clin Infect Dis 2015; 61(11): 1637-44. 
 
 
 
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          112 
 Appendix A  
Study Visit Type  
Recruitment  
Screening  
Enrollment / 
Vaccination  
Clinic or 
Home Visit  
Clinic or 
Home Visit  
Follow -up 
Follow -up 
Follow -up 
Follow -up 
Follow -up 
Early Termination  
Unscheduled  
Study Visit 
Number  
R˜ 
VOO  
V01 
V02 
V03 
V04 
V05 
V06 
V07 
V08 
 
Study Day  
 
1st & 2nd 
Trimesters  
-30 to 1 
D1 
D4+1 
D8+3d  
D31±4d  
Birth + 3d  
Birth + 
42d±5d  
Birth + 
70d±5d or 
130d±5d  
Birth + 
180d±7d  
  
EGA or Infant 
Age 
10-26 
weeks  
14-26 
weeks  
14-26 
weeks  
15-27 
weeks  
15-27 
weeks  
19-31 
weeks  
Birth 
1.5 
months  
2 5 or 4.5 
months  
6 months  
  
Introduction to Study, 
Recruiting  X Xm Xm          
Obtain Informed 
Consent∞   X Xm¬          
Review Eligibility 
Criteria   X Xm¬   X¬       
Medical History@  X Xm¬ X¬ X¬ X¬ X¬ X¬˜ X¬˜ X¬˜ X¬ X¬ 
Concomitant 
Medications√@  X Xm¬ X¬ X¬ X¬ X! X˜ X˜ X˜ X! X! 
Vaccination History@  X Xm¬ X¬ X¬ X¬ X!      
Vital Signs$ (Oral 
Temperature%, Pulse, 
and BP)   X X†   X X    X X 
Height and Weight  X Xm          
Targeted Physical 
Exam {}   X X m¬†#   X X X X X X  X 
Ultrasound to Date 
Pregnancy   X           
Venous Blood 
Collection from 
Mother ( 30 mL)    X†  
 X X  
 X   
Cord Blood (up to 30 
mL)       X      
Venous Blood from 
Infant (5 mL )       X& X X X   
Obtain Breastmilk 
Sample from Mother 
(10-20 mL )     
  Xψ X X X   
Pre-Administration 
Solicited Event 
Assessments    X†  
    
    
Randomize and 
Vaccinate Mother    X          
30-minute Evaluation 
After Study 
Vaccination    X  
    
    
DMID Protocol 16- 0024  Version 3.0 
Pertussis Vaccine in Pregnant Women  24 July 2019  
 ______________________________________________________________________________________________________  
 
 
          114 
 {}Targeted  physical examination, if indicated based on review of complete or interim medical history. An 
examination performed by a pregnant woman’s own obstetrical clinician may also provide data when a targeted 
exam is called for. An exam should be performed for both the mother and infant if indicated for pregnant women on and after birth.  
$Vital signs assessed on Day 1 (Visit 01) prior to the study vaccination will be considered as baseline and used to 
determine eligibility.  For the birth visit, vital signs record ed for the mother as part of her delivery record may be 
used in lieu of study personnel performing vital sign measurements.  
#A physical examination performed as part of routine antenatal care or a study -specific brief exam may be used. 
!If within  [ADDRESS_576810] vaccination.  
˟ If within [ADDRESS_576811] vaccination.  
*SAEs and new -chronic onset medical conditions only after Day 31 or delivery, whichever occurs earlier.  
+Only medically attended AEs will be recorded.  
ψ The first colostrum collection may occur within  the first 4 days of life of the infant.  
˚ Infant vital signs will include axillary temperature, heart rate,  and respi [INVESTIGATOR_697] . 
ˠ If not performed as routine care, these measurements, except for weight, may be taken by [CONTACT_452435] 7 days of infant life. Weights will only be recorded when obtained at birth.  
˜ Procedures will be performed on both mot her and infant . 
Ω Only infant height, weight , and head circumference will be recorded at these visits.  
 